Clinical trial register · Italy

Clinical Trials in Bergamo, 2026

Every study on the ClinicalTrials.gov registry that lists a site in Italy and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV

Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 6778 matching records held by the registry are in this view. Synced 08 Oct 2026, 03:19 UTC

6778

Studies in scope

all four open statuses

4069

Recruiting now

open to new participants

1018

Lead sponsors

across recruiting studies

Top sites

Milan 2843 Bologna 1305 Roma 1274 Naples 984 Rome 967

Trials with a site in Bergamo

Status

Study

Lead sponsor

Phase

Enrol

Sites in Italy

Start

Not yet open

Endoscopic Management of Biliopancreatic Disease in the Lombardy Pancreas Units

NCT07418164Pancreatic Cancer, Biliopancreatic Diseases, Periampullary Neoplasms

IRCCS San Raffaele

Observational

2,500

Bergamo, Brescia, Cremona, Legnano, Mantua, Milan, Monza, Pavia

2026-10-31

Not yet open

Biological Analysis of MABs in NHL in a Translational Prospective Observational Study Within Italian Clinical Practice

NCT07767799B-Cell Non-Hodgkin Lymphoma (NHL)

Fondazione Italiana Linfomi - ETS

Observational

1,000

Candiolo, Castelfranco Veneto, Alessandria, Aviano, Bari, Bergamo, Bologna, Brescia

2026-10

Not yet open

Study of Izalontamab Brengitecan (BMS-986507) in Combination With Osimertinib Versus Osimertinib Monotherapy or Osimertinib in Combination With Platinum-based Chemotherapy for EGFRmt Non-small Cell Lung Cancer (IZABRIGHT-Lung02)

NCT07680790Non-Small Cell Lung Cancer

DrugsIza-bren·Osimertinib·Pemetrexed·Cisplatin

Bristol-Myers Squibb

Phase 3

850

Meldola, Candiolo, Bergamo, Brescia, Milan, Pavia, Verona

2026-09-30

Recruiting

A Study To Assess the Safety, Tolerability, and Efficacy of Imzokitug in Combination With Pumitamig and Platinum-Doublet Chemotherapy (PDCT) Versus Pumitamig and PDCT as First-line Treatment for Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

NCT07680764Locally Advanced Non-Small Cell Lung Cancer (NSCLC), Metastatic Non-Small Cell Lung Cancer (NSCLC)

DrugsImzokitug·Vedolizumab·Infliximab·Pumitamig

Bristol-Myers Squibb

Phase 2

160

Misterbianco, Bari, Bergamo, Milan, Ravenna, Rozzano (MI)

2026-09-10

Recruiting

A Phase 3 Study of INCA033989 Versus Best Available Therapy in Participants With Essential Thrombocythemia

NCT07623200Essential Thrombocythemia

DrugINCA033989

Incyte Corporation

Phase 3

426

Bari, Bergamo, Bologna, Catania, Florence, Genova, Meldola, Milan

2026-09-08

Recruiting

A First-in-Human Study of KK2223 in Participants With Relapsed or Refractory T Cell Non-Hodgkin Lymphoma

NCT07192471T-cell NHL (PTCL or CTCL)

Kyowa Kirin, Inc.

Phase 1

Candiolo, Bergamo, Bologna, Torino

2026-09-02

Not yet open

BV-CHP Real-life and Biological Evidences in Patients With sALCL

NCT07467317Anaplastic Large Cell Lymphoma

Fondazione Italiana Linfomi - ETS

Observational

100

Avellino, Aviano, Bari, Bergamo, Bologna, Candiolo, Legnano, Milan

2026-09

Not yet open

Mitigating Mitochondrial RNA Release During Aging to Control Inflammation and Senescence

NCT07596615Aging, Inflammation, Healthy Ageing

Mario Negri Institute for Pharmacological Research

Not applicable

Bergamo, Ranica

2026-09

Recruiting

A Study to Investigate CV Outcomes With Elecoglipron Compared With Placebo in Adult Participants With HFpEF or HFmrEF

NCT07761117Heart Failure With Preserved Ejection Fraction (HFpEF), Heart Failure With Mildly Reduced Ejection Fraction (HFmrEF)

DrugElecoglipron

AstraZeneca

Phase 3

6,950

Ancona, Bergamo, Brescia, Milan, Pavia, Perugia, Riccione, Salerno

2026-08-24

Recruiting

Evaluation of the Efficacy and Safety of Magnetic Resonance Angiography (MRA) Using Gadopiclenol Compared to Gadoterate Meglumine in the Assessment of Steno-occlusive Disease in Adult Patients With Suspected Vascular Disease

NCT07348640Steno-occlusive Disease

DrugsGadopiclenol·Gadoterate meglumine

Guerbet

Phase 3

315

Bergamo, Cagliari, Chieti, Milan, Roma, Treviso

2026-07-28

Recruiting

A Study of BMS-986504 Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5)

NCT07492680Solid Tumors

DrugsNavlimetostat·Pumitamig·Temozolomide·Cetuximab

Bristol-Myers Squibb

Phase 2

260

Siena, Bergamo, Milan, Naples, Perugia

2026-07-27

Recruiting

PET Guided Dose Reduction for InvOlved Site Radiotherapy In Early sTage Unfavourable Hodgkin Lymphoma

NCT07256158Hodgkin Lymphoma

Fondazione Italiana Linfomi - ETS

Phase 3

518

Alessandria, Avellino, Aviano, Bergamo, Brescia, Cagliari, Candiolo, Catania

2026-07-10

Recruiting

Avoiding Recooling After Normothermic Machine Perfusion in Liver Transplantation

NCT07692490Liver Transplantation (LT), Ischemia-Reperfusion Injury, Early Allograft Dysfunction

The Mediterranean Institute for Transplantation and Advanced Specialized Therapies

Not applicable

170

Ancona, Bari, Bergamo, Bologna, Genova, Modena, Padova, Palermo

2026-07-07

Recruiting

Symbiotic-Lung-14: A Study to Learn About the Study Medicine Called PF08634404 in Combination With Chemotherapy in Adult Participants With Transformed Small Cell Lung Cancer

NCT07476287Small Cell Lung Cancer, Small Cell Lung Cancer ( SCLC ), Transformed Small Cell Lung Cancer, Lung Neoplasms

DrugPF-08634404

Pfizer

Phase 2

Bergamo, Roma, Orbassano

2026-07-02

Recruiting

Stroke Care During the COVID-19 Pandemic

NCT07795021Stroke (CVA) or TIA

Dr. Yaroslav Winter

Observational

40,000

Bergamo

2026-07-01

Not yet open

Overviewing Real-World Outcomes to Boost Interventional Management of CAlcified Coronary Lesions: the OROBICA Registry.

NCT07566403Coronary Artery Disease (CAD), Calcific Coronary Arteriosclerosis, Intravascular Lithotripsy; Rotational Atherectomy; OFDI, Orbital Atherectomy

Papa Giovanni XXIII Hospital

Observational

3,000

Bergamo

2026-06-30

Recruiting

[68Ga]BED003 PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications

NCT07702292Colorectal Cancer, Epithelial Ovarian Cancer, Gastric Cancer (GC), Pancreatic Ductal Adenocarcinoma (PDAC)

Blue Earth Diagnostics

Phase 2

Bergamo, Monza, Roma, Milan

2026-06-30

Recruiting

Optimising Adjuvant Chemotherapy Prescription in Young Patients With Hormone-dependent Breast Cancer Using Genomic Tests

NCT07106632Early Breast Cancer, Premenopausal Breast Cancer, HR+/HER2- Breast Cancer

UNICANCER

Phase 3

3,380

Aviano, Bergamo, Carpi, Crema, Florence, Genova, Lecco, Meldola

2026-06-26

Recruiting

Cevostamab in Combination With Pomalidomide and Dexamethasone Versus Standard of Care in Participants With Previously Treated Multiple Myeloma

NCT07555938Multiple Myeloma

DrugsCevostamab·Elotuzumab·Carfilzomib·Pomalidomide

Hoffmann-La Roche

Phase 3

380

Meldola, Bergamo, Rozzano

2026-06-23

Recruiting

A Study of ARC-02 in B-cell NHL

NCT07691606B-cell Non Hodgkin Lymphoma

DrugRituximab

Taiho Oncology, Inc.

Phase 1

140

Aviano, Bergamo, Bologna, Rozzano

2026-06-22

Recruiting

A Phase IIIb Study to Evaluate Camizestrant Plus Ribociclib in ER-positive, HER2-negative Advanced Breast Cancer

NCT07647328ER-Positive HER2-Negative Breast Cancer

DrugsCamizestrant·Ribociclib

AstraZeneca

Phase 3

150

Aviano, Bergamo, Genova, Milan, Naples

2026-06-15

Recruiting

Phase Ib/II Platform Study of Multiple Anti-Cancer Agents in Participants With Metastatic Prostate Cancer

NCT07590934Metastatic Prostate Cancer

DrugsAZD2287·FPI-2265·Palacaparib·Docetaxel

AstraZeneca

Phase 1/2

152

Bergamo, Meldola, Milan, Roma

2026-06-03

Recruiting

A Study to Learn More About How Safe Finerenone is, When it is Taken for a Longer Time With Standard Treatment, in Children and Young Adults With Heart Failure and Left Ventricular Systolic Dysfunction

NCT07192952Left Ventricular Systolic Dysfunction, Heart Failure (Pediatric)

DrugFinerenone

Bayer

Phase 3

117

Bergamo, Bologna, Genova, Milan, Naples, Padova, Roma, Torino

2026-06-01

Recruiting

A Study of How the Medicine Called "Etrasimod" Works in Children With the Gut Disease Called Ulcerative Colitis

NCT07470879Colitis, Ulcerative

DrugEtrasimod

Pfizer

Phase 2

Bergamo, Milan, Florence

2026-05-28

Recruiting

A Phase I Study to Evaluate the Safety and Dosimetry of Imaging With 68Ga-OncoACP3 in Prostate Cancer

NCT07600554Prostate Cancer

Drug[68Ga]Ga-OncoACP3

Philogen S.p.A.

Phase 1

Bergamo, Milan

2026-05-27

Recruiting

RO7771950 Versus Tucatinib in Combination With Trastuzumab and Capecitabine in People With Locally Advanced or Metastatic Breast Cancer That is Human Epidermal Growth Factor Receptor 2 (HER2)-Positive

NCT07413939HER2-positive Breast Cancer

DrugsZN-A-1041·Tucatinib·Trastuzumab·Capecitabine

Hoffmann-La Roche

Phase 2/3

650

Naples, Meldola, Parma, Aviano, Rome, Bergamo, Brescia, Milan

2026-05-21

Recruiting

A Clinical Trial of MK-1045 in People With B-cell Acute Lymphoblastic Leukemia (MK-1045-005)

NCT07570173B-cell Acute Lymphoblastic Leukemia

DrugsAvtozma·Tyenne·Siltuximab·MK-1045

Merck Sharp & Dohme LLC

Phase 2/3

340

Bergamo, Rome

2026-05-18

Recruiting

An Open Label Extension (OLE) Study (Following Completion of CTQJ230A12301) to Evaluate Long-term Safety and Tolerability of Pelacarsen (TQJ230)

NCT07517263Cardiovascular Disease and Lipoprotein(a)

DrugPelacarsen

Novartis Pharmaceuticals

Phase 3

5,700

Ancona, Bergamo, Bologna, Brescia, Cona, Florence, Pozzilli, Milan

2026-05-11

Recruiting

Evaluating Adherence to Guideline-Directed Medical Therapy in Patients With Advanced Heart Failure

NCT07560982Heart Failure

DrugGDMT

Università Vita-Salute San Raffaele

Observational

300

Bergamo, Milan

2026-05-08

Recruiting

A Clinical Trial of Adjuvant Intismeran (V940) With or Without Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) in High-Risk Stage I Non-Small Cell Lung Cancer (V940-014)

NCT07513376Non-small Cell Lung Cancer

DrugsPembrolizumab Formulated with Berahyaluronidase Alfa·Intismeran autogene

Merck Sharp & Dohme LLC

Phase 3

876

Bergamo, Milan, Florence, Perugia, Novara, Roma

2026-05-04

Recruiting

Establishing a Reference Framework for Outcomes After Machine-Preserved Liver Transplantation in Europe

NCT07585890End-stage Liver Disease (ESLD), Acute Liver Failure, Liver Cirrhosis, Liver Transplantation

University Medical Center Groningen

Observational

10,000

Bari, Bergamo, Pisa, Torino

2026-04-21

Recruiting

MONTEROSA - Italian Multicenter Observational Study to Evaluate Time to Clinical Hepatic Decompensation, Quality of Life, Effectiveness, and Safety of Tremelimumab Plus Durvalumab in Patients With Advanced or Unresectable Hepatocellular Carcinoma Who Have Received no Prior Systemic Treatment.

NCT07607769Hepatocellular Carcinoma

AstraZeneca

Observational

200

Ancona, Bergamo, Foggia, Meldola, Milan, Modena, Naples, Padova

2026-04-16

Recruiting

Investigation of REcurrence Mechanisms to Adjuvant osimertINib in Radically Resected EGFR-mutated NSCLC Patients

NCT07363252EGFR-mutated NSCLC

DrugOsimertinib

Gruppo Oncologico Italiano di Ricerca Clinica

Observational

100

Bari, Bergamo, Bologna, Misterbianco, Monza, Milan, Modena, Padova

2026-04-14

Recruiting

A Phase II Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib Plus Fulvestrant Versus Placebo Plus Ribociclib Plus Fulvestrant in Participants With Advanced Breast Cancer

NCT07405801Breast Cancer

DrugsInavolisib·Ribociclib·Fulvestrant

Hoffmann-La Roche

Phase 2

Naples, Meldola, Rome, Bergamo, Milan

2026-04-07

Recruiting

Antenatal Stress and Infants In MAR

NCT07408453Pregnancy and Medically Assisted Reproduction

IRCCS Eugenio Medea

Observational

100

Bergamo

2026-04

Recruiting

A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight and Type 2 Diabetes

NCT07351058Obesity or Overweight, Type 2 Diabetes Mellitus

Hoffmann-La Roche

Phase 3

1,600

Bergamo, Catanzaro, Bologna, Rome, Milan, Palermo, Perugia

2026-03-23

Recruiting

A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight Without Type 2 Diabetes

NCT07351045Obesity or Overweight

Hoffmann-La Roche

Phase 3

2,000

Bergamo, Bari, Catanzaro, Bologna, Rome, San Donato Milanese (MI), Palermo, Pisa

2026-03-16

Recruiting

LEVEL-2: LEVosimendan to Improve Exercise Limitation in Patients With PH-HFpEF-2

NCT07288398Pulmonary Hypertension Associated With HFpEF

DrugTNX-103

Tenax Therapeutics, Inc.

Phase 3

540

Acquaviva delle Fonti, Bergamo, Messina, Milan, Pavia, Pisa, Roma, Rozzano

2026-03-03

Recruiting

Three Different GHDT ( Goal Hemodynamic Directed Therapy) Strategies for Intraoperative Fluid Management Optimization During Major Abdominal Surgery: A Randomized Controlled Trial

NCT06871150Hemodynamic

ASST Sette Laghi

Not applicable

150

Bergamo, Rozzano, Varese

2026-03-02

Not yet open

AVF-MONITOR POC Proof-of-concept Study

NCT07318025Hemodyalysis

Mario Negri Institute for Pharmacological Research

Not applicable

Bergamo

2026-03

Recruiting

Study to Evaluate Switching to Brelovitug for the Treatment of CHD in Participants Receiving Bulevirtide

NCT07454837Chronic Hepatitis D

DrugBulevirtide

Mirum Pharmaceuticals, Inc.

Phase 2/3

120

Bergamo, Milan

2026-02-26

Recruiting

A Study to Evaluate the Impact of Efgartigimod on Overall Disease Experience of People Suffering From Generalized Myasthenia Gravis (gMG) in Italy

NCT07595653Generalized Myasthenia Gravis (gMG), gMG

argenx

Observational

100

Acquaviva delle Fonti, Ancona, Bari, Bergamo, Bologna, Catanzaro, Florence, Genova

2026-02-25

Recruiting

Neurological Events and Unforeseen Risks After Locoregional-anesthesia

NCT07238933Regional Anesthesia, Regional Anesthesia Block

Societa Italiana Anestesia Analgesia Rianimazione e Terapia Intensiva

Observational

3,396

Bergamo, Brescia, Rozzano, Padova

2026-02-18

Recruiting

Creation of Compression Anastomosis Using the GT Metabolic Magnet System

NCT07431723Anastomosis, Functional, Colorectal

GT Metabolic Solutions, Inc.

Not applicable

Bergamo, Naples

2026-02-16

Recruiting

A Study to Learn More About the Change in the Blood Levels of Transthyretin When Participants With Transthyretin Amyloidosis With Cardiomyopathy Switch From Tafamidis to Acoramidis

NCT07298044Transthyretin Amyloid Cardiomyopathy

DrugAcoramidis

Bayer

Phase 4

Bergamo, Bologna, Florence, Lecce, Milan, Naples, Padova, Pavia

2026-02-13

Recruiting

A Phase 2b Study Evaluating Oral VH4524184 Regimens in Treatment Naïve Persons With HIV-1 (INNOVATE Study)

NCT07202546HIV Infections

DrugsVH4524184·Dovato·Dolutegravir/Lamivudine

ViiV Healthcare

Phase 2

186

Bergamo, Milan, Roma

2026-02-11

Active, closed

A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma

NCT07266441Multiple Myeloma

DrugRamantamig

Janssen Research & Development, LLC

Phase 2

168

Bergamo, Bologna, Cuneo, Florence, Palermo, Pavia, Pescara, Roma

2026-02-08

Recruiting

Outcomes in ARMs: Comparison Between Surgical Techniques in Patients With Perineal or Vestibular Fistula - a Multicenter Italian Study

NCT07438691Anorectal Malformations

Meyer Children's Hospital IRCCS

Observational

500

Florence, Bergamo, Brescia, Catania, Lecce, Modena, Novara, Padova

2026-02-05

Recruiting

Group-Based Exercise Intervention to Prevent Cognitive and Motor Decline

NCT07494149Healthy, Older Adults

University of Bergamo

Not applicable

158

Bergamo

2026-02-01

Recruiting

A Study to Investigate Bowel Cleansing With PLENVU® Compared to Sodium Picosulfate in Participants Aged 1 to < 18 Years of Age in Preparation for Colonoscopy

NCT07218523Bowel Cleansing Prior to Clinical Procedures

DrugsPicoprep·Plenvu

Norgine

Phase 3

212

Bergamo, Florence, Messina, Milan, Naples, Roma

2025-12-29

Active, closed

A Study to Assess Zipalertinib Versus Placebo in Participants With Early Stage NSCLC With Uncommon EGFR Mutations, Following Complete Tumor Resection

NCT07128199Lung Cancer, Adjuvant, Post-surgical, EGFR

DrugZipalertinib

Taiho Oncology, Inc.

Phase 3

360

Alessandria, Ancona, Bergamo, Bologna, Catania, Meldola, Livorno, Legnano

2025-12-22

Recruiting

A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)

NCT07174336Breast Neoplasms, Neoplasm Metastasis

DrugsTersolisib·Exemestane·Anastrozole·Abemaciclib

Eli Lilly and Company

Phase 3

800

Bergamo, Bologna, Florence, Genova, Meldola, Milan, Misterbianco, Monza

2025-12-22

Recruiting

A Real-life Observational Study in Severe Eosinophilic Asthma Adult Participant Treated With Benralizumab in Italy

NCT07214753Severe Eosinophilic Asthma

DrugsFasenra·Benralizumab

AstraZeneca

Observational

335

Salerno, Padova, Teramo, Treviso, Varese, Bari, Bergamo, Bologna

2025-12-20

Recruiting

ADAPT Forward 1 - ISA1 - a Study to Evaluate Empasiprubart IV as add-on Therapy to Efgartigimod IV in Participants With AChR-Ab Seropositive Generalized Myasthenia Gravis With a Partial Clinical Response to Efgartigimod

NCT07284420AChR-Ab Seropositive Generalized Myasthenia Gravis, Myasthenia Gravis, MG, gMG

DrugsEmpasiprubart·Efgartigimod

argenx

Phase 2

Bergamo, Milan, Naples

2025-12-19

Recruiting

ADAPT Forward - Master Protocol of a Platform Study to Evaluate the Safety and Efficacy of Multiple Regimens in Participants With Myasthenia Gravis

NCT07294170Myasthenia Gravis, MG, gMG, Generalized Myasthenia Gravis

DrugsEmpasiprubart·Efgartigimod

argenx

Observational

Bergamo, Milan, Naples

2025-12-19

Recruiting

A Research Study to Look at the Effect of Ziltivekimab on Plaque in the Blood Vessels of the Heart, Compared to Placebo, in People With a Heart Attack

NCT07301034Myocardial Infarction

DrugZiltivekimab

Novo Nordisk A/S

Phase 3

332

Rome, Bergamo, Messina, Rivoli, Genova, Novara, Orbassano, San Donato Milanese

2025-12-18

Recruiting

Study for Frail Patients With Newly Diagnosed Multiple Myeloma Treated With Daratumumab With Teclistamab or Talquetamab.

NCT07107529Multiple Myeloma (MM)

DrugsTalquetamab·Teclistamab·Daratumumab

European Myeloma Network B.V.

Phase 2

150

Ascoli Piceno, Bari, Bergamo, Bologna, Bolzano, Como, Milan, Novara

2025-12-12

Recruiting

ASPEN-09-03: A Study of Evorpacept in Combination With Trastuzumab and Chemotherapy in Metastatic HER2-Positive Breast Cancer

NCT07007559Breast Cancer, Metastatic

DrugsEvorpacept·Eribulin·Herceptin·Vinorelbine

ALX Oncology Inc.

Phase 2

120

Torrette, Genova, Bergamo, Bologna, Milan, Monza, Novara

2025-12-10

Recruiting

Voll Degradable Shoulder Spacer FIH Study

NCT07208448Massive Rotator Cuff Tear

Voll Medical Technologies Ltd.

Not applicable

Bergamo, Bologna

2025-12-09

Recruiting

A Study of Clinical Outcomes in Participants With EGFR Mutated Advanced Non-Small Cell Lung Cancer (NSCLC) in a Real-World Setting

NCT07230691Carcinoma, Non-Small-Cell Lung

Janssen Research & Development, LLC

Observational

380

Avellino, Aviano, Bari, Bergamo, Brescia, Candiolo, Catania, Catanzaro

2025-12-03

Recruiting

A ELN-Multicenter Study on Phenotypic Evolution and Clinical Outcomes

NCT07203768Polycythemia Vera, Thrombocythemia

FROM- Fondazione per la Ricerca Ospedale di Bergamo- ETS

Observational

678

Pavia, Vicenza, Alessandria, Bergamo, Bologna, Brescia, Florence, Milan

2025-12-01

Recruiting

Study of Revumenib in Combination With Intensive Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia (AML) With a NPM1 Mutation

NCT07211958Acute Myeloid Leukemias

DrugRevumenib

Syndax Pharmaceuticals

Phase 3

468

Monza, Pesaro, Alessandria, Bergamo, Bologna, Brescia, Candiolo, Florence

2025-11-25

Recruiting

A Study to Learn More About How Well Finerenone Works, How Safe it is, and How it Moves Into, Through, and Out of the Body Compared to Placebo When Taken With Standard Treatment in Children With Heart Failure and Left Ventricular Systolic Dysfunction

NCT07188805Left Ventricular Systolic Dysfunction, Heart Failure (Pediatric)

DrugFinerenone

Bayer

Phase 3

111

Bergamo, Bologna, Genova, Milan, Naples, Padova, Roma, Torino

2025-11-19

Active, closed

A Study to Find Out Whether BI 765423 Has an Effect on Lung Function in People With Idiopathic Pulmonary Fibrosis (IPF) With or Without Standard Treatment

NCT07036523Idiopathic Pulmonary Fibrosis

Boehringer Ingelheim

Phase 2

Bergamo, Florence, Naples, Roma, Torino

2025-11-13

Recruiting

A Study to Evaluate the Efficacy and Safety of Remibrutinib in Secondary Progressive Multiple Sclerosis

NCT07225504Secondary Progressive Multiple Sclerosis (SPMS)

DrugRemibrutinib

Novartis Pharmaceuticals

Phase 3

1,275

Ancona, Bergamo, Foggia, Pozzilli, Pavia, Roma, Gallarate, Naples

2025-11-11

Recruiting

Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer

NCT07085767Breast Cancer, Locally Advanced Breast Cancer, Metastatic Breast Cancer, ER Positive Breast Cancer

DrugsPalazestrant·Ribociclib·Letrozole

Olema Pharmaceuticals, Inc.

Phase 3

1,000

Naples, Bologna, Aviano, Rome, Genoa, Bergamo, Milan, Monza

2025-11-03

Recruiting

A Study to Evaluate the Safety and Preliminary Signs of Efficacy of [177Lu]Lu-OncoFAP-23 Alone or in Combination With L19-IL2 as a Treatment of Metastatic FAP-positive Solid Tumors

NCT06640413FAP

DrugL19IL2

Philogen S.p.A.

Phase 1

Bergamo, Milan, Naples

2025-10-31

Recruiting

A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)

NCT07165028Metabolic Dysfunction-Associated Steatotic Liver Disease

DrugsRetatrutide·Tirzepatide

Eli Lilly and Company

Phase 3

4,500

Bergamo, Bologna, Florence, Milan, Naples, Padova, Palermo, Roma

2025-10-15

By invitation

Clinical Impact Through AI-assisted MS Care - A Prospective Multi-center Study

NCT07032246Multiple Sclerosis, Radiologically Isolated Syndrome, Clinically Isolated Syndrome

icometrix

Not applicable

750

Bergamo, Milan

2025-10-09

Recruiting

A Clinical Study of Calderasib (MK-1084) and Other Treatments for Participants With Non-Small Cell Lung Cancer (MK-1084-007/KANDLELIT-007)

NCT07190248Non-small Cell Lung Cancer

Drugs) Berahyaluronidase alfa·Calderasib·Paraplatin·Pemetrexed

Merck Sharp & Dohme LLC

Phase 3

675

Bolzano, Modena, Meldola, Udine, Rome, Bergamo, Rozzano, Statte

2025-10-08

Recruiting

A Study to Evaluate the Effect of GDC-4198 Alone and in Combination With Giredestrant Versus Abemaciclib and Giredestrant in Participants With Locally Advanced or Metastatic Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor-Negative (HER2-) Breast Cancer

NCT07100106Breast Cancer

DrugsRGT-419B·Giredestrant·Abemaciclib

Genentech, Inc.

Phase 1/2

285

Bologna, Meldola, Bergamo, Brescia, Milan

2025-10-07

Recruiting

A Study to Evaluate INCA035784 in Participants With Myeloproliferative Neoplasms

NCT07008118Myeloproliferative Neoplasms

Incyte Corporation

Phase 1

120

Bergamo, Florence, Milan, Verona

2025-10-01

Recruiting

"Referral Attivo" Delta, Dallo Screening Alla Presa in Carico.

NCT07317011Hepatitis, Delta

FROM- Fondazione per la Ricerca Ospedale di Bergamo- ETS

Observational

244

Bergamo

2025-10-01

Recruiting

Breast Cancer RElapsed in Patients Treated With Adjuvant CDK4/6 Inhibitors:

NCT07180693Adjuvant Therapy, CDK4/6 Inhibitor

European Institute of Oncology

Observational

750

Bergamo, Brescia, Brindisi, Crema, Lecco, Legnano, Milan, Modena

2025-09-29

Recruiting

A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)

NCT07144280Non-small Cell Carcinoma, Non-Small Cell Lung Cancer Metastatic, Non-Small Cell Lung Carcinoma

DrugsPF-08046054·Docetaxel

Pfizer

Phase 3

680

Aviano, Rome, Roma, Florence, Verona, Bergamo, Caserta, Genova

2025-09-29

Recruiting

Long-Term Low-Intervention SafEty and Clinical Outcomes Clinical Study of LivmArli® in Patients With Alagille Syndrome or Progressive Familial Intrahepatic Cholestasis in the European Union (LEAP-EU)

NCT07290257Alagille Syndrome, Progressive Familial Intrahepatic Cholestasis

DrugMaralixibat

Mirum Pharmaceuticals, Inc.

Phase 4

230

Bergamo, Palermo

2025-09-25

Recruiting

International Study of the SING IMT™ Prosthesis in Pseudophakic patiEnts With Stable Moderate to Profound Bilateral Central vIsion Impairment Due to adVancEd AMD / PERSPECTIVE Study

NCT07164378Age - Related Macular Degeneration (AMD)

VisionCare, Inc.

Not applicable

Bari, Bergamo, Ferrara, Florence, Roma

2025-09-23

Active, closed

A Study to Evaluate Two Dosing Regimens of Subcutaneous Nivolumab in Combination With Intravenous Ipilimumab and Chemotherapy in Participants With Previously Untreated Metastatic or Recurrent Non-Small Cell Lung Cancer (NSCLC)

NCT06946797Non-Small Cell Lung Cancer

DrugsNivolumab and rHuPH20·Yervoy·Ipilimumab·Pemetrexed

Bristol-Myers Squibb

Phase 2

Meldola, Udine, Bergamo, Florence, Novara

2025-09-19

Recruiting

Barriers Limiting OCT Penetration in Clinical Practice

NCT07193693Coronary Artery Disease (CAD) (E.G., Angina, Myocardial Infarction, and Atherosclerotic Heart Disease (ASHD))

Consorzio Futuro in Ricerca

Observational

1,000

Bergamo, Genova

2025-09-15

Recruiting

A Study to Evaluate TAR-210 Versus Intravesical Chemotherapy Treatment in Participants With High Risk Non-Muscle-Invasive Bladder Cancer

NCT06919965Non-Muscle Invasive Bladder Neoplasms

DrugsErdafitinib·Mitomycin C·Gemcitabine

Janssen Research & Development, LLC

Phase 3

220

Bergamo, Brescia, Genova, Milan, Naples, Roma, Sanatorio San Luigi, Udine

2025-09-10

Not yet open

Vagal Nerve Stimulation to Treat Disorders of Consciousness

NCT07077135Disorder of Consciousness

Fondazione IRCCS San Gerardo dei Tintori

Not applicable

106

Brescia, Monza, Bergamo, Como, Genova, Milan, Padova, Parma

2025-09-01

Not yet open

Long-term Assessment of Chlormethine Gel in Mycosis Fungoides

NCT07046663Cutaneous T-Cell Lymphoma/Mycosis Fungoides

Fondazione Italiana Linfomi - ETS

Observational

190

Ancona, Bergamo, Bologna, Brescia, Cagliari, Catania, Florence, Genova

2025-09

Recruiting

Phase 2 Study of ADX-038 in Complement-Mediated Kidney Disease

NCT06989359IgAN, C3G, Complement-mediated Kidney Disease, IgA Nephropathy (IgAN)

ADARx Pharmaceuticals, Inc.

Phase 2

Bergamo, Bologna, Pavia

2025-08-28

Active, closed

A Research Study to See How Insulin Icodec Helps People With Type 1 Diabetes Control Their Blood Sugar

NCT07160816Diabetes Mellitus, Type 1

DrugInsulin icodec

Novo Nordisk A/S

Observational

245

Milan, Turin, Livorno, Lucca, Bergamo, Catanzaro, Naples, Perugia

2025-08-28

Recruiting

A Trial Evaluating Brelovitug (BJT-778) vs Bulevirtide for the Treatment of Chronic Hepatitis Delta Infection (AZURE-2)

NCT07200908Chronic Hepatitis D Infection

DrugBulevirtide

Mirum Pharmaceuticals, Inc.

Phase 3

172

Bergamo, Milan, Pisa, Roma

2025-08-27

Active, closed

A Study Comparing Tarlatamab, Durvalumab, Carboplatin, and Etoposide Versus Durvalumab, Carboplatin, and Etoposide in First-line Extensive Stage Small-Cell Lung Cancer (ES-SCLC)

NCT07005128Small-cell Lung Cancer, Extensive Stage Small-cell Lung Cancer

DrugsTarlatamab·Etoposide·Durvalumab·Carboplatin

Amgen

Phase 3

350

Bari, Bergamo, Meldola (FC), Milan, Roma, Verona

2025-08-18

Recruiting

A Study of GSK5764227 in Participants With Relapsed Small Cell Lung Cancer (SCLC) [EMBOLD SCLC-301]

NCT07099898Neoplasms, Lung

DrugsRis-Rez·Risvutatug rezetecan·Topotecan

GlaxoSmithKline

Phase 3

420

Milan, Bergamo, Genova, Orbassano, Pisa, Siena, Verona

2025-08-11

Recruiting

A Study of Metastases Free Survival With Saruparib vs Placebo Added to a Standard RT/ADT in Men With High-risk Prostate Cancer With a BRCA Mutation

NCT06952803Prostate Cancer

DrugsPrednisolone/prednisone·Saruparib·Abiraterone

AstraZeneca

Phase 3

700

Arezzo, Bari, Bergamo, Chieti, Genoa, Milan, Naples, Palermo

2025-08-06

Recruiting

Early Ravulizumab Treatment Of Anti- AChR Antibody-Positive Generalized Myasthenia Gravis

NCT06967480Generalized Myasthenia Gravis, Anti-AChR Antibody Positive

DrugRavulizumab

Alexion Pharmaceuticals, Inc.

Observational

Bergamo, Bologna, Brescia, Florence, Imperia, Lecco, Messina, Milan

2025-07-31

Recruiting

Observational Study on Lutetium (177Lu) Vipivotide Tetraxetan to Treat Metastatic Castration Resistant Prostate Cancer

NCT07093801Metastatic Castration Resistant Prostate Cancer

Novartis Pharmaceuticals

Observational

300

Alessandria, Asti, Bergamo, Brescia, Catania, Meldola, Cona, Foggia

2025-07-30

Active, closed

A Study to Evaluate Tobevibart+Elebsiran in Participants With Chronic HDV Infection Not Virologically Suppressed With Bulevirtide

NCT07128550Viral Hepatitis

DrugsTobevibart·Elebsiran·Bulevirtide

Vir Biotechnology, Inc.

Phase 3

150

Bergamo, Foggia, Milan, Pisa, Torino

2025-07-30

Recruiting

EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease

NCT07064473Diabetes Mellitus, Type 2, Hypertension, Cardiovascular Diseases

DrugsVicadrostat·Dapagliflozin

Boehringer Ingelheim

Phase 3

11,800

Acquaviva Delle Fonti (BA), Bergamo, Brescia, Catania, Catanzaro, Chieti, Cona (FE), Coppito (AQ)

2025-07-22

Recruiting

A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)

NCT07060807Breast Neoplasms

DrugsPatritumab deruxtecan·Pegylated liposomal doxorubicin·Abraxane·Xeloda

Merck Sharp & Dohme LLC

Phase 3

1,000

Bergamo, Milan, Naples, Roma

2025-07-21

Recruiting

A Study to Evaluate Patient-Reported Satisfaction, Effectiveness, and Safety of Atezolizumab in Participants Treated in Routine Clinical Practice

NCT07284121Lung Cancer, Hepatocellular Carcinoma

DrugsTecentriq·Atezolizumab

Hoffmann-La Roche

Observational

700

Lecce, Naples, Modena, Ravenna, Rome, Genoa, Bergamo, Milan

2025-07-15

Recruiting

Fluid Management of Acute Decompensated Heart Failure Subjects Treated With Reprieve System (FASTR-II) (IDE-G210258)

NCT06898515Acute Decompensated Heart Failure

DrugFurosemide

Reprieve Cardiovascular, Inc

Phase 3

400

Ancona, Bergamo, Milan

2025-07-14

Recruiting

Patiromer and Diet/hrQoL in Chronic Dialysis

NCT06858280Hyperkalaemia, Chronic Kidney Disease Stage 3 and 4, Dietary Intervention

DrugPatiromer

Mario Negri Institute for Pharmacological Research

Phase 3

Bergamo

2025-07-08

Recruiting

A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)

NCT06966700Breast Neoplasms, Triple Negative Breast Neoplasms, HR Low-Positive/HER2-Negative Breast Neoplasms

DrugsEpirubicin·Adriamycin·Xeloda·Sacituzumab tirumotecan

Merck Sharp & Dohme LLC

Phase 3

2,400

Monza, Livorno, Ancona, Bergamo, Genova, Milan, Pisa, Reggio Emilia

2025-06-30

Active, closed

Observational Study on the Clinical Profile of Patients With Uncontrolled Severe Asthma Treated With Tezepelumab in Italy

NCT06948396Asthma

DrugTezepelumab

AstraZeneca

Observational

315

Cittadella (PD), Montebelluna (TV), Aosta, Avellino, Bari, Bergamo, Brescia, Cagliari

2025-06-25

Recruiting

Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity

NCT07037459Heart Failure With Preserved Ejection Fraction, Heart Failure With Mildly Reduced Ejection Fraction, Obesity

DrugMaridebart cafraglutide

Amgen

Phase 3

5,056

Bari, Bergamo, Brescia, Cortona AR, Foggia, Forlì, Milan, Naples

2025-06-25

Recruiting

Emotional Distress in Patients With Metastatic Breast Cancer in First Line of Therapy

NCT06994377Metastatic Breast Cancer

European Institute of Oncology

Observational

1,000

Ancona, Aviano, Bagno a Ripoli, Bari, Bergamo, Brescia, Brindisi, Busto Arsizio

2025-06-25

Recruiting

Efficacy and Safety of Remibrutinib After Switching From Ocrelizumab in Participants Living With Relapsing Multiple Sclerosis.

NCT06846281Relapsing Multiple Sclerosis

DrugsRemibrutinib·Ocrelizumab

Novartis Pharmaceuticals

Phase 3

400

Bergamo, Foggia, Genova, Milan, Pavia, Roma

2025-06-23

Recruiting

A Study to Assess the Efficacy, Safety, and Tolerability of IMVT-1402 as Treatment for Adult Participants With Graves' Disease

NCT07018323Graves' Disease

DrugIMVT-1402

Immunovant Sciences GmbH

Phase 2

210

Rozzano, Acquaviva delle Fonti, Bergamo, Cuneo, Livorno, Milan, Naples, Pavia

2025-06-19

Recruiting

Percutaneous Intercostal Cryoneuromodulation Onset Timing.

NCT07081620Cryotherapy Effect, Pectus Excavatum

Papa Giovanni XXIII Hospital

Observational

Bergamo

2025-06-07

Active, closed

A Study to Evaluate Axatilimab Versus Best Available Therapy in Participants With Chronic Graft Versus Host Disease After at Least 2 Prior Lines of Systemic Therapy

NCT06821542Chronic Graft-versus-host-disease

DrugAxatilimab

Incyte Corporation

Phase 3

Alessandria, Ancona, Bergamo, Bologna, Brescia, Catania, Florence, Genova

2025-06-04

Recruiting

A Phase III Study of AZD0780 on Major Adverse CV Events in Patients With a History of ASCVD Events or at High Risk for a First Event

NCT07000357Cardiovascular Disease

DrugAZD0780

AstraZeneca

Phase 3

15,100

Altamura, Arzignano, Bergamo, Bologna, Brescia, Caserta, Catania, Cona

2025-06-04

Recruiting

A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)

NCT06852222Leukemia, Myeloid, Acute

DrugsBleximenib·Azacitidine·Venetoclax

Janssen Research & Development, LLC

Phase 3

600

Bergamo, Bologna, Brescia, Meldola, Milan, Pavia, Perugia, Pesaro

2025-06-04

Recruiting

Study to Assess the Efficacy and Safety of IMVT-1402 in Participants With Mild to Severe Generalized Myasthenia Gravis

NCT07039916Generalized Myasthenia Gravis

DrugIMVT-1402

Immunovant Sciences GmbH

Phase 3

231

Bergamo, Milan, Naples, Rome

2025-05-27

Recruiting

A Study of Zolbetuximab Together With Pembrolizumab and Chemotherapy in Adults With Gastric Cancer

NCT06901531Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer, Locally Advanced Unresectable Gastric Adenocarcinoma or Cancer, Metastatic Gastric Adenocarcinoma or Cancer, Metastatic Gastroesophageal Junction (GEJ) Adenocarcinoma

DrugsZolbetuximab·Adrucil·Capecitabine·Oxaliplatin

Astellas Pharma Global Development, Inc.

Phase 3

500

Bergamo, Bologna, Brescia, Candiolo, Cremona, Florence, Meldola, Milan

2025-05-22

Recruiting

A Study to Test Whether Vicadrostat (BI 690517) in Combination With Empagliflozin Helps People With Heart Failure and a Weak Pumping Function of the Left Side of the Heart

NCT06935370Heart Failure

DrugsVicadrostat·Dapagliflozin

Boehringer Ingelheim

Phase 3

4,200

Bergamo, Naples, Pavia, Pisa, Roma, Rozzano

2025-05-20

Recruiting

A Study of Duvelisib Versus Gemcitabine or Bendamustine in Participants With Relapsed/Refractory Nodal T Cell Lymphoma With T Follicular Helper (TFH) Phenotype

NCT06522737Lymphoma

DrugsDuvelisib·Bendamustine·Gemcitabine

SecuraBio

Phase 3

124

Alessandria, Bergamo, Bologna, Naples, Rome

2025-05-19

Recruiting

A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001)

NCT06925737Prostate Cancer, Prostatic Neoplasms

DrugsIfinatamab Deruxtecan·Prednisolone·Prednisone·Docetaxel

Merck Sharp & Dohme LLC

Phase 3

1,440

Milan, Rozzano, Rome, Siena, Arezzo, Bergamo, Foggia, Terni

2025-05-13

By invitation

A Post Approval Multicenter 10 Year Follow-up Observational Trial of Marketed Product - MP01 vs. Surgical Standard of Care (SSOC) Used for the Treatment of Joint Surface Lesions of the Knee

NCT06916728Knee Injuries, Joint Surface Knee Lesions

Smith & Nephew, Inc.

Observational

170

Bergamo, Milan

2025-05-05

Recruiting

Lung Ultrasound for Guiding Antibiotic Use in Pediatric Pneumonia

NCT06921993Pneumonia Childhood, Pneumonia, Lung Ultrasound, Antibiotic Stewardship

Meyer Children's Hospital IRCCS

Not applicable

659

Florence, Bergamo, Bologna, Brescia, Genova, Milan, Naples, Novara

2025-04-24

Active, closed

Extension Study of Sotatercept in People With Pulmonary Hypertension (MK-7962-023)

NCT06814145Hypertension, Pulmonary

DrugSotatercept

Merck Sharp & Dohme LLC

Phase 2

440

Bergamo, Pavia, Roma

2025-04-16

Recruiting

A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer

NCT06790693Breast Cancer

DrugsCDK4/6i·Inavolisib·Letrozole

Hoffmann-La Roche

Phase 3

450

Tricase (LE), Caserta, Naples, Bologna, Meldola, Modena, Rome, Bergamo

2025-04-09

Recruiting

BRCA Mutation Carriers' Platform a Multicenter Study

NCT07253051BRCA1 Mutation, BRCA2 Mutation

Fondazione Policlinico Universitario Agostino Gemelli IRCCS

Observational

10,000

Avellino, Aviano, Bari, Bergamo, Catania, Cuneo, Enna, Florence

2025-04-05

Recruiting

PRospective Observational Study of STereotactic Body rAdiation Therapy With Androgen Deprivation Therapy for Organ-confined High-risk Prostate Cancer: the PROSTAR Trial

NCT06949254High Risk Prostate Cancer

Istituto Clinico Humanitas

Observational

Bergamo, Milan, Rozzano

2025-04-04

Active, closed

Comparing the Performance of Serum Creatinine and Cystatin C-based GFR Estimations in Predicting Directly Measured GFR in Patients With or Without Nephrotic Syndrome

NCT06797609Nephrotic Syndrome

Mario Negri Institute for Pharmacological Research

Observational

Bergamo, Ranica

2025-04-01

Recruiting

ePro Diary - HDV ( MACROLIVER )

NCT07442760HDV, HDV Infection, Hepatitis

FROM- Fondazione per la Ricerca Ospedale di Bergamo- ETS

Observational

Bergamo

2025-03-31

Recruiting

Randomised Clinical Trial to Investigate Efficacy and Safety of Benralizumab 30 mg SC as an add-on Therapy in Uncontrolled Eosinophilic Asthma Patients Treated With Medium-dose ICS-LABA Compared to Conventional Escalation to High-dose ICS-LABA Treatment

NCT06750289Eosinophilic Asthma

AstraZeneca

Phase 3

400

Bari, Bergamo, Brescia, Cagliari, Catanzaro, Genoa, Milan, Modena

2025-03-28

Recruiting

Trial on the Biological and Clinical Effects of Acetyl-L-carnitine in ALS

NCT06126315Amyotrophic Lateral Sclerosis

Mario Negri Institute for Pharmacological Research

Phase 2/3

246

Brescia, Bergamo, Milan, Naples, Novara, Padova, Palermo, Pergine Valsugana

2025-03-26

Recruiting

Routine Outcome Monitoring and Feedback Informed Therapy in Italy

NCT06356961Feedback, Psychological

University of Bergamo

Not applicable

180

Bergamo

2025-03-25

Recruiting

Imeroprubart in Adult Participants With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

NCT07032662Chronic Inflammatory Demyelinating Polyneuropathy

Immunovant Sciences GmbH

Phase 2

162

Bergamo, Bologna, Brescia, Milan, Pavia, Pisa, Roma, Siena

2025-03-18

Recruiting

Phase III Study Investigating Heart Failure and Cardiovascular Death With Baxdrostat in Combination With Dapagliflozin

NCT06677060Heart Failure

DrugBaxdrostat/dapagliflozin

AstraZeneca

Phase 3

11,300

Alessandria, Bari, Bergamo, Brescia, Chiavari, Cona, Foggia, Milan

2025-03-14

Recruiting

Clonal Hematopoiesis of Indeterminate Potential in Heart Failure.

NCT06626685Heart Failure

FROM- Fondazione per la Ricerca Ospedale di Bergamo- ETS

Observational

300

Bergamo

2025-03-10

Recruiting

Blood Flow Conditions and Sounds in AVFs

NCT06411353End Stage Renal Disease

Mario Negri Institute for Pharmacological Research

Not applicable

Bergamo

2025-03-01

Not yet open

"Observational, Retrospective and Prospective, Non-interventional, Multicentre on the Use of Genomic Testing in the Management of Early Stage HR+/HER2- Breast Cancer"

NCT06871501Breast Cancer

Consorzio Oncotech

Observational

1,000

Avellino, Bergamo, Bologna, Brescia, Termoli, Caserta, Cuneo, Ferrara

2025-03

Recruiting

Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1

NCT06767514Non-Small Cell Lung Cancer

DrugsIvonescimab·Pembrolizumab

Summit Therapeutics

Phase 3

780

Rome, Bari, Bergamo, Milan, Orbassano, Parma, Peschiera del Garda

2025-02-27

Recruiting

stereOtactic Body RadIothErapy for exTracranial oligomeTastAtic Breast Cancer: Multi Institutional Retrospective Database

NCT07397585Breast Cancer, Oligometastasis

Istituto Clinico Humanitas

Observational

300

Benevento, Bergamo, Brindisi, Brescia, Campobasso, Florence, Genova, Messina

2025-02-25

Recruiting

A Study to Evaluate the Efficacy and Safety of DNTH103 in Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CAPTIVATE)

NCT06858579Chronic Inflammatory Demyelinating Polyneuropathy

DrugClaseprubart

Dianthus Therapeutics

Phase 3

256

Bergamo, Bologna, Genova, Gussago, Milan, Modena, Monza, Pavia

2025-02-10

Active, closed

A Study to Investigate the Efficacy, Safety and Tolerability of Remibrutinib Versus Placebo in Adult Patients With Generalized Myasthenia Gravis

NCT06744920Generalized Myasthenia Gravis

DrugRemibrutinib

Novartis Pharmaceuticals

Phase 3

180

Bergamo, Orbassano

2025-02-07

Recruiting

Robotic Rehabilitation of the Upper Limb in Subacute Stroke

NCT06839482Stroke

IRCCS San Raffaele Roma

Not applicable

130

Rome, San Vito sullo Ionio, Costa Masnaga, Fiorenzuola d'Arda, Passignano sul Trasimeno, Ummbertide, Bergamo, Catanzaro

2025-02-06

Recruiting

Long Term Safety of Preoperative Percutaneous Intercostal Cryoneurolysis

NCT07657845Cryo Analgesia, Pectus Surgery

Papa Giovanni XXIII Hospital

Observational

Bergamo

2025-02-02

Recruiting

Phase 4 Paediatric Study to Evaluate Sonazoid Safety and Efficacy for Contrast-Enhanced Ultrasound Liver Imaging

NCT06639828Focal Liver Lesions

GE Healthcare

Phase 4

Bergamo, Genoa

2025-01-20

Recruiting

MIRAMACS, Multicenter Italian Study on RAdial Mechanically Assisted Circulatory Support

NCT07458074Heart Failure

IRCCS Azienda Ospedaliero-Universitaria di Bologna

Observational

400

Bergamo, Bologna, Genova, Milan, Padova, Palermo, Pavia, Roma

2025-01-10

Recruiting

A Study to Evaluate Efficacy and Safety of Hydeal Cyst® Intravesical Instillations in Patients Treated With Intravesical Chemotherapy or Immunotherapy in Non-muscle Invasive Bladder Cancer

NCT06245603Non-muscle Invasive Bladder Cancer

Istituto Oncologico Veneto IRCCS

Not applicable

200

Bergamo, Bologna, Foggia, Padova, Palermo, Udine, Verona

2024-12-20

Recruiting

Study With Omecamtiv Mecarbil (CK-1827452) to Treat Chronic Heart Failure With Severely Reduced Ejection Fraction

NCT06736574Heart Failure, Heart Failure With Reduced Ejection Fraction

Cytokinetics

Phase 3

1,800

Brescia, Rimini, Arzignano, Bergamo, Milan, Sesto San Giovanni, Perugia, Cona

2024-12-19

Active, closed

A Trial to Evaluate Efficacy and Safety of Buloxibutid in People With Idiopathic Pulmonary Fibrosis.

NCT06588686Idiopathic Pulmonary Fibrosis (IPF)

Vicore Pharma AB

Phase 2

378

Ancona, Bergamo, Monza, Roma, Turin

2024-12-09

Recruiting

Elacestrant + Everolimus in Patients ER+/HER2-, ESR1mut, Advanced Breast Cancer Progressing to ET and CDK4/6i.

NCT06382948Advanced Breast Cancer, ER-positive Breast Cancer, HER2-negative Breast Cancer, ESR1 Gene Mutation

DrugsElacestrant·Everolimus

MedSIR

Phase 3

300

Bergamo, Cagliari, Florence, Genova, Livorno, Milan, Modena, Monza

2024-12-05

Recruiting

A Research Study Comparing How Well Different Doses of the Medicine NNC0519-0130 Can Reduce Kidney Damage in People Living With Chronic Kidney Disease

NCT06717698Chronic Kidney Disease

DrugSemaglutide

Novo Nordisk A/S

Phase 2

465

L’Aquila, Chieti, Bologna, Bergamo, Brescia, Milan, Pisa, Roma

2024-12-02

Active, closed

A Study to Evaluate the Effectiveness of Long-acting (LA) Cabotegravir (CAB) + Rilpivirine (RPV) LA When Given to Participants With Detectable HIV-1

NCT06694805HIV Infections

DrugsRpv La·B/F/TAF·Cabotegravir

ViiV Healthcare

Phase 3

326

Bari, Bergamo, Milan, Roma

2024-12-02

Recruiting

An Outcome Analysis of Primary Membranous Nephropathy

NCT06242327Membranous Nephropathy

Mario Negri Institute for Pharmacological Research

Observational

500

Bergamo, Ranica

2024-11-29

Active, closed

Trial to Evaluate Acasunlimab and Pembrolizumab Combination Superiority Over Standard of Care Docetaxel in Non-Small Cell Lung Cancer (ABBIL1TY NSCLC-06)

NCT06635824PD-L1-positive, Locally Advanced (Unresectable Stage IIIB/C) or Metastatic NSCLC

DrugsDocetaxel·Pembrolizumab

Genmab

Phase 3

191

Monza, Rozzano, Naples, Aviano, Rome, Orbassano, Bergamo, Candiolo

2024-11-25

Recruiting

Stereotactic Body Radiotherapy (SBRT) for Reirradiation of Inoperable Lung Lesions

NCT07401615Non Small Cell Lung Cancer, Pulmonary Stereotactic Radiotherapy

Istituto Clinico Humanitas

Observational

150

Bergamo, Bologna, Catania, Milan, Rozzano, Naples, Roma, Venezia

2024-11-25

Active, closed

A Study of Sequential Therapy With Daplusiran/Tomligisiran (DAP/TOM) Followed by Bepirovirsen in Participants Living With Chronic Hepatitis B (CHB)

NCT06537414Chronic Hepatitis B Virus Infection, Hepatitis B

DrugBepirovirsen

GlaxoSmithKline

Phase 2

283

Bergamo, Florence, Milan, Naples, Padova, Pisa, Roma

2024-11-11

Active, closed

Study of Lunsekimig (SAR443765) Compared With Placebo in Adults With High-risk Asthma

NCT06676319Asthma

DrugsBudesonide/Formoterol·Lunsekimig

Sanofi

Phase 2

556

Torette, Monserrato, Cona, Genoa, Milan, Rozzano, Rome, Bergamo

2024-11-07

Active, closed

Induction Chemo+Immunotherapy in Resectable Epithelioid and Biphasic Pleural Mesothelioma (CHIMERA Study)

NCT06155279Pleural Mesothelioma

DrugKeytruda

Istituto Oncologico Veneto IRCCS

Phase 2

Bergamo, Roma, Rozzano, Aviano, Alessandria, Ferrara, Padova, Parma

2024-11-06

Recruiting

A Non-interventional, Post-authorisation Safety Study of Patients Treated With Efgartigimod Alfa

NCT06298565Myasthenia Gravis

DrugEfgartigimod

argenx

Observational

680

Bergamo, Bologna, Naples, Pisa, Roma

2024-11-04

Recruiting

HRQoL and Financial Toxicity in Patients With VEXAS Syndrome

NCT06657846VEXAS

Gruppo Italiano Malattie EMatologiche dell'Adulto

Observational

100

Ancona, Bergamo, Bologna, Brescia, Candiolo, Florence, Milan, Naples

2024-11-01

Recruiting

A Clinical Trial Evaluating the Safety and Efficacy of a New Light Combination Therapy Addressing Intermediate AMD

NCT06557369Intermediate AMD

Oculox Technologies SA

Not applicable

Bergamo

2024-11

Active, closed

PTLD: Multicentric Retrospective Study

NCT06422715PTLD

Fondazione Italiana Linfomi - ETS

Observational

241

Milan, Aviano, Bergamo, Bologna, Brescia, Cagliari, Cuneo, Florence

2024-10-30

Active, closed

Phase 2 Study Evaluating Rapcabtagene Autoleucel in Participants With Diffuse Cutaneous Systemic Sclerosis

NCT06655896Scleroderma, Diffuse

DrugsRapcabtagene autoleucel·Rituximab

Novartis Pharmaceuticals

Phase 2

Ancona, Bergamo, Brescia, Genova, Milan, Pescara, Perugia, Pisa

2024-10-29

Recruiting

A Long-term Extension (LTE) Study of Guselkumab in Pediatric Participants

NCT06663332Crohns Disease, Colitis, Ulcerative, Arthritis, Psoriatic, Arthritis, Juvenile

DrugGuselkumab

Janssen Research & Development, LLC

Phase 3

196

Bergamo, Bologna, Roma, San Giovanni Rotondo, Trieste

2024-10-29

Recruiting

Kidney Perfusion With or Without Absorption

NCT06374121Kidney Replacement

Mario Negri Institute for Pharmacological Research

Not applicable

Bergamo

2024-10-22

Recruiting

Trauma Molecular Processes

NCT07683169Traumatic Brain Injury

Mario Negri Institute for Pharmacological Research

Observational

500

Bergamo, Monza

2024-10-18

Active, closed

A Study Observing Everyday Effectiveness and Safety of the Drug Elafibranor in Participants With Primary Biliary Cholangitis Who Are Receiving Ongoing Treatment

NCT06447168Primary Biliary Cholangitis

Ipsen

Observational

424

Bergamo, Catania, Florence, Milan, Novara, Roma

2024-10-14

Active, closed

Evaluation of Maralixibat in Pruritus Associated With General Cholestatic Liver Disease (EXPAND)

NCT06553768Cholestatic Liver Disease (Except ALGS, PFIC, PBC and PSC)

DrugMaralixibat

Mirum Pharmaceuticals, Inc.

Phase 3

Bergamo, Palermo, Rome

2024-10-14

Recruiting

Clinical Epidemiology in Contemporary Patients With Myelofibrosis.

NCT06533813Myelofibrosis

FROM- Fondazione per la Ricerca Ospedale di Bergamo- ETS

Observational

617

Alessandria, Bergamo, Bologna, Catania, Florence, Milan, Monza, Naples

2024-10-14

Active, closed

A Study to Evaluate the Safety and Efficacy of Axatilimab in Combination With Ruxolitinib in Participants With Newly Diagnosed Chronic Graft-Versus-Host Disease

NCT06388564Chronic Graft-versus-host-disease

DrugsAxatilimab·Ruxolitinib·Methylprednisolone·Prednisolone

Incyte Corporation

Phase 2

130

Bergamo, Bologna, Milan, Rome, Rozzano, Torino

2024-10-11

Recruiting

A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%

NCT06561386Non-small Cell Lung Cancer

DrugsRelatlimab·Pemetrexed·Nivolumab·Cisplatin

Bristol-Myers Squibb

Phase 3

1,000

Bari, Ravenna, Monza, Milan, Naples, Rome, Peschiera del Garda, Bergamo

2024-10-07

Recruiting

Primary Cardiac Lymphoma: Italian Multicenter Experience

NCT05819528Primary Cardiac Lymphoma

Fondazione Italiana Linfomi - ETS

Observational

Bergamo, Brescia, Ferrara, Milan, Perugia, Pisa, Roma, Sassari

2024-10-02

Recruiting

Camera-based Endoscopy Allows Spontaneous Breathing Diagnostic Management in Neonates With Tracheoesophageal Fistula

NCT07687628Tracheoesophageal Fistula, Esophageal Atresia With Tracheo-esophageal Fistula

Papa Giovanni XXIII Hospital

Observational

Bergamo

2024-10-01

Recruiting

Diagnosis and Treatment of Late Neurological Ischemic Deficit in Patients Suffering From Subarachnoid Hemorrhage.

NCT06804421Aneurysmal Subarachnoid Haemorrhage, Delayed Ischemic Neurological Deficit

Fondazione IRCCS San Gerardo dei Tintori

Observational

1,400

Bergamo, Bologna, Brescia, San Fermo della Battaglia, Cremona, Florence, Genova, Lecco

2024-09-28

Recruiting

A Study to Investigate the Safety and Efficacy of GSK4532990 Compared With Placebo in Adult Participants Aged 18 to 70 Years With Alcohol-related Liver Disease

NCT06613698Liver Diseases, Alcoholic

DrugGSK4532990

GlaxoSmithKline

Phase 2

393

Bergamo, Bologna, Messina, Milan, Padova, Roma

2024-09-27

Active, closed

A Study to Assess Efficacy and Safety of Efgartigimod PH20 SC in Adults With Ocular Myasthenia Gravis

NCT06558279Myasthenia Gravis, Ocular

argenx

Phase 3

141

Bergamo, Bologna, Milan, Naples, Roma

2024-09-18

Recruiting

SPAGO: Sirolimus Paclitaxel Angiographic Gain Objective

NCT06373601Coronary Artery Disease, Stenosis Coronary, Coronary Artery Lesion, Percutaneous Coronary Intervention

Fondazione Evidence per Attività e Ricerche Cardiovascolari ONLUS

Not applicable

140

Mercogliano, Bergamo, Brescia, Ferrara, Milan, Rozzano, Naples, Orbassano

2024-09-05

Active, closed

EASi-KIDNEY™ (The Studies of Heart & Kidney Protection With BI 690517 in Combination With Empagliflozin)

NCT06531824Kidney Disease, Chronic

DrugsVicadrostat·Dapagliflozin

Boehringer Ingelheim

Phase 3

11,000

Alessandria, Asti, Bari, Bergamo, Bologna, Cagliari, Chieri, Chieti

2024-08-30

Recruiting

Study of Volrustomig as Monotherapy or in Combination With Anti- Cancer Agents in Participants With Advanced/Metastatic Solid Tumors

NCT06535607Sub-study 1 Cervical Cancer (Volrustomig Monotherapy), Sub-study 2 Head and Neck Squamous Cell Carcinoma (Volrustomig Monotherapy), Sub-study 3 Head and Neck Squamous Cell Carcinoma (Volrustomig in Combination With Chemotherapy), Sub-study 4 Esophageal Squamous Cell Carcinoma (Volrustomig in Combination With Chemotherapy)

DrugsVolrustomig·Adrucil·Paclitaxel·Cisplatin

AstraZeneca

Phase 2

257

Alessandria, Bergamo, Orbassano

2024-08-22

Recruiting

A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer

NCT06435429Metastatic HER2-positive Breast Cancer

DrugsZanidatamab·Eribulin·Vinorelbine·Trastuzumab

Jazz Pharmaceuticals

Phase 3

550

Aviano, Bergamo, Bologna, Milan, Modena, Monza, Padova, Pavia

2024-08-13

Recruiting

Rehabilitation With and Without Robot and Allied Digital Technologies in Stroke Patients

NCT06547827Stroke

Fondazione Don Carlo Gnocchi ETS

Not applicable

596

Acerenza, Bari, Bergamo, Catania, Catanzaro, Crotone, Foggia, Genova

2024-08-12

Recruiting

Saruparib (AZD5305) Plus Camizestrant or Plus Endocrine Therapy, Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast Cancer

NCT06380751Advanced Breast Cancer

DrugsSaruparib·Camizestrant·Exemestane·Anastrozole

AstraZeneca

Phase 3

788

Bergamo, Bologna, Milan, Modena, Naples, Padova, Reggio Emilia, Rome

2024-08-01

Recruiting

LUNAR-2: TTFields With Pembrolizumab + Platinum-based Chemotherapy for Metastatic NSCLC

NCT06216301Metastatic Non-small Cell Lung Cancer

DrugPembrolizumab

NovoCure GmbH

Phase 3

734

Alessandria, Bergamo, Ferrara, Meldola, Pesaro, Roma, Rome, Siena

2024-07-31

Active, closed

ITAKOS - Italian Observation, Multicenter, Prospective Study of Ofatumumab in RRMS Patients

NCT06345157Multiple Sclerosis, Relapsing-Remitting

DrugOfatumumab

Novartis Pharmaceuticals

Observational

379

Ancona, L’Aquila, Bari, Bergamo, Chieti, Catania, Catanzaro, Cona

2024-07-30

Active, closed

1 vs 7 RATG Infusions in Renal Transplantation

NCT06374095Kidney Replacement

DrugsRATG·Basiliximab·Belatacept·Thymoglobulin

Mario Negri Institute for Pharmacological Research

Observational

Bergamo

2024-07-30

Active, closed

PHESGO Maintenance After T-DXd Short Induction for HER2+ Unresectable Locally Recurrent or Metastatic Breast Cancer

NCT06172127HER2-positive Breast Cancer

DrugsPhesgo·Trastuzumab deruxtecan

MedSIR

Phase 2

165

Bergamo, Milan, Novara, Roma

2024-07-22

Recruiting

Real World Pediatric Oncology Rehabilitation in Italy ( ReWori )

NCT07368582Pediatric Cancer, Pediatric Cancer Patients, Pediatric Oncology, Rehabilitation

Associazione Italiana Ematologia Oncologia Pediatrica

Observational

249

Bergamo, Bologna, Bolzano, Bosisio Parini, Brindisi, Catania, Conegliano, Florence

2024-07-19

Active, closed

A Trial to Learn if the Combination of Fianlimab, Cemiplimab, and Chemotherapy is Safe and Works Better Than the Combination of Cemiplimab and Chemotherapy in Adult Patients With Non-Small Cell Lung Cancer That Can be Treated With Surgery

NCT06161441Resectable Non-small Cell Lung Cancer

DrugsFianlimab·Cemiplimab·Paraplatin·Taxol

Regeneron Pharmaceuticals

Phase 2

195

Naples, Ferrara, Piacenza, Florence, Livorno, Bergamo, Milan, Pesaro

2024-07-16

Recruiting

GIM27-THERapy: a Study to Describe the Effectiveness of Tucatinib in Combination With Capecitabine and Trastuzumab in the Treatment of Metastatic HER-2 Positive Breast Cancer Patients in Real World Setting

NCT07583485Breast Cancer

Fondazione Oncotech

Observational

300

Avellino, Ancona, Aviano, Bari, Barletta, Bergamo, Caserta, Genova

2024-07-01

Active, closed

ARTEMIS - A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With a Heart Attack

NCT06118281Cardiovascular Risk, Acute Myocardial Infarction (AMI)

DrugZiltivekimab

Novo Nordisk A/S

Phase 3

10,000

Chieti, Caserta, Cona (Ferrara), Latina, Bergamo, San Donato Milanese, Turin, Pordenone

2024-06-25

Recruiting

Efficacy and Safety of a New Formulation of Oral Cladribine Compared With Placebo in Participants With Generalized Myasthenia Gravis (MyClad)

NCT06463587Generalized Myasthenia Gravis

DrugCladribine

Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany

Phase 3

264

Bergamo, Bologna, Genova, Milan, Pavia, Rome, Treviso

2024-06-25

Recruiting

A Study to Test Whether Vicadrostat in Combination With Empagliflozin Helps People With Heart Failure

NCT06424288Heart Failure

DrugsVicadrostat·Dapagliflozin

Boehringer Ingelheim

Phase 3

6,712

Bergamo, Foggia, Genova, Naples, Pavia, Roma, Rozzano

2024-06-17

Active, closed

A Study Comparing Pre- and Post-Change Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma

NCT06425991Multiple Myeloma

DrugTeclistamab

Janssen Research & Development, LLC

Phase 1

108

Ancona, Bergamo, Brescia, Meldola, Pisa, Rome

2024-06-07

Recruiting

IMC-F106C Regimen Versus Nivolumab Regimens in Previously Untreated Advanced Melanoma (PRISM-MEL-301)

NCT06112314Advanced Melanoma

DrugsBrenetafusp·Relatlimab·Opdivo·Nivolumab

Immunocore Ltd

Phase 3

680

Bari, Bergamo, Meldola, Milan, Modena, Naples, Padova, Perugia

2024-06-05

Recruiting

Italian PheNotypes Obstructive Sleep Apnea Study

NCT06872242Sleep Apnea

Istituto Auxologico Italiano

Observational

5,000

Acri, Ancona, Bari, Bergamo, Bologna, Cagliari, Catania, Corigliano-Rossano

2024-06-01

Recruiting

A Study to Evaluate the Efficacy and Safety of Pegozafermin in Participants With Compensated Cirrhosis Due to MASH

NCT06419374Metabolic Dysfunction-Associated Steatohepatitis (MASH) / Nonalcoholic Steatohepatitis (NASH) With Compensated Cirrhosis

DrugPegozafermin

89bio, Inc.

Phase 3

762

Bergamo, Foggia, Milan, Novara, Palermo, Roma, Rome, Rozzano

2024-05-24

Recruiting

MYTHS-MR Trial (MYocarditis THerapy With Steroids in Patients With Mildly Reduced Ejection Fraction)

NCT05974462Acute Myocarditis

DrugsSolu-Medrol·Methylprednisolone

University Hospital, Antwerp

Phase 3

174

Milan, Arezzo, Bergamo, Brescia, Florence, Lecco, Pavia, Pisa

2024-05-24

Recruiting

A Study of Ifinatamab Deruxtecan Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer

NCT06203210Small Cell Lung Cancer

DrugsAmrubicin·Ifinatamab Deruxtecan·Lurbinectedin·Topotecan

Daiichi Sankyo

Phase 3

540

Bari, Bergamo, Brescia, Catania, Catanzaro, Genova, Milan, Monza

2024-05-21

Recruiting

Safety and Efficacy of 3 Dose Levels of NMD670 in Adult Patients With Myasthenia Gravis

NCT06414954Myasthenia Gravis, Myasthenia Gravis, MuSK

NMD Pharma A/S

Phase 2

Bergamo, Bologna, Genova, Milan, Naples, Pisa, Roma

2024-05-16

Active, closed

Use of Elranatamab in Patients With High-risk Smoldering Multiple Myeloma

NCT06183489Smoldering Multiple Myeloma

DrugElranatamab

European Myeloma Network B.V.

Phase 2

Bari, Bergamo, Florence, Genova, Meldola, Novara, Padova, Pavia

2024-05-14

Recruiting

Precision Medicine in Patients With Unresectable CholAngiocarcinoma: RadioEmbolization and Combined Biological Therapy

NCT06375915Intrahepatic Cholangiocarcinoma

DrugsDurvalumab·Gemcitabine·Cisplatin

Francesco De Cobelli

Phase 2

Bergamo, Milan, Naples, Pisa

2024-04-30

Recruiting

A Study to Evaluate TAR-210 Versus Single Agent Intravesical Cancer Treatment in Participants With Bladder Cancer

NCT06319820Non-Muscle Invasive Bladder Neoplasms

DrugGemcitabine

Janssen Research & Development, LLC

Phase 3

641

Arezzo, Bergamo, Brescia, Milan, Roma, Rozzano, Torino

2024-04-18

Active, closed

A Study to Investigate Long-term Safety and Tolerability of Tolebrutinib in Participants With Multiple Sclerosis.

NCT06372145Relapsing Multiple Sclerosis, Secondary Progressive Multiple Sclerosis, Progressive Relapsing Multiple Sclerosis

DrugTeriflunomide

Sanofi

Phase 3

2,500

Pozzilli, Milan, Rome, Florence, Bergamo, Cagliari, Catania, Chieti

2024-04-16

Recruiting

Study to Evaluate the Effect of Balcinrenone/Dapagliflozin in Patients With Heart Failure and Impaired Kidney Function

NCT06307652Heart Failure and Impaired Kidney Function

AstraZeneca

Phase 3

3,850

Acquaviva delle Fonti, Bari, Bergamo, Brescia, Catania, Catanzaro, Cona, Cortona

2024-04-12

Recruiting

Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations

NCT06357533Non-Small Cell Lung Cancer

DrugsRilvegostomig·Dato-DXd·Keytruda·Pembrolizumab

AstraZeneca

Phase 3

675

Bergamo, Genoa, Milan, Monza, Padova, Pavia, Ravenna, Roma

2024-04-11

Recruiting

Integrated Molecular and Clinical Profiling to Improve Disease Characterization and Outcome Prediction in Nodal Marginal Zone Lymphoma

NCT05700149Nodal Marginal Zone Lymphoma

International Extranodal Lymphoma Study Group (IELSG)

Observational

300

Alessandria, Bari, Bergamo, Brescia, Catania, Cona, Florence, Messina

2024-04-11

Recruiting

A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)

NCT06312137Non Small Cell Lung Cancer

DrugsSacituzumab tirumotecan·Pemetrexed·Gemcitabine·Paclitaxel

Merck Sharp & Dohme LLC

Phase 3

780

Misterbianco, Meldola, Milan, Monza, Rome, Florence, Bergamo, Genova

2024-04-03

Recruiting

Transitional ePRO Diary Liver (Transitional-ePRO)

NCT06342557Liver Transplant

FROM- Fondazione per la Ricerca Ospedale di Bergamo- ETS

Observational

250

Bergamo

2024-03-28

Recruiting

Study on Efficacy and Safety of Givinostat Versus Hydroxyurea in Patients With Polycythemia Vera

NCT06093672Polycythemia Vera

DrugHydroxyurea

Italfarmaco

Phase 3

220

Bari, Reggio Calabria, Bologna, Meldola, Reggio Emilia, Udine, Rome, Bergamo

2024-03-26

Recruiting

A Study of Guselkumab in Pediatric Participants With Moderately to Severely Active Crohn's Disease

NCT05923073Crohn's Disease

DrugsTremfya·Guselkumab

Janssen Research & Development, LLC

Phase 3

120

Alessandria, Bergamo, Bologna, Florence, Milan, Roma

2024-03-13

Recruiting

A Study of Mirikizumab (LY3074828) in Pediatric Participants With Crohn's Disease

NCT05509777Crohn's Disease

DrugMirikizumab

Eli Lilly and Company

Phase 3

Alessandria, Bergamo, Bologna, Florence, Milan, Roma

2024-03-13

Recruiting

A Study Evaluating the Efficacy and Safety of Pegozafermin in Participants With MASH and Fibrosis (ENLIGHTEN-Fibrosis)

NCT06318169Metabolic Dysfunction-Associated Steatotic Liver Disease (MASH) / Nonalcoholic Steatohepatitis (NASH) With Fibrosis

DrugPegozafermin

89bio, Inc.

Phase 3

1,350

Bergamo, Foggia, Milan, Modena, Naples, Novara, Palermo, Roma

2024-03-13

Recruiting

A Multicenter Trial Assessing the Impact of Lipoprotein(a) Lowering With Pelacarsen (TQJ230) on the Progression of Calcific Aortic Valve Stenosis

NCT05646381Aortic Stenosis

DrugPelacarsen

Novartis Pharmaceuticals

Phase 2

502

Ancona, Bergamo, Bologna, Brescia, Caserta, Cona, Pozzilli, Milan

2024-03-07

Recruiting

A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors

NCT06172478Advanced Solid Tumor, Melanoma, Head and Neck Cancer, Gastric Cancer

DrugPatritumab deruxtecan

Daiichi Sankyo

Phase 2

740

Bergamo, Genova, Naples, Verona

2024-02-26

Active, closed

A Study to Evaluate the Efficacy, Safety, and Tolerability of Using an Oral Once-daily 2 Drug Regimen Compared to an Oral Once-daily 3 Drug Regimen for the Treatment of Human Immunodeficiency Virus (HIV)-1 in Adults Who Have Not Previously Taken Antiretroviral Therapy

NCT05979311HIV, HIV Infections

DrugsBictegravir·Dolutegravir·Emtricitabine·Lamivudine

ViiV Healthcare

Phase 3

307

Bari, Bergamo, Padova, Pavia, Sassari

2024-02-21

Active, closed

Outcome of ADPKD With Octreotide LAR

NCT06193616Autosomal Dominant Polycystic Kidney

DrugOctreotide

Mario Negri Institute for Pharmacological Research

Observational

Bergamo

2024-02-12

Active, closed

A Study to Test an Oral Medicine, Belumosudil, in Combination With Corticosteroids in Participants at Least 12 Years of Age With Newly Diagnosed Chronic Graft Versus Host Disease.

NCT06143891Chronic Graft Versus Host Disease

DrugsBelumosudil·Prednisolone·Prednisone

Sanofi

Phase 3

260

Torette, Genoa, Milan, Rozzano, Rome, Turin, Bergamo, Bologna

2024-01-23

Active, closed

A Study of Guselkumab in Pediatric Participants With Moderately to Severely Active Ulcerative Colitis

NCT06260163Colitis, Ulcerative

DrugsTremfya·Guselkumab

Janssen Research & Development, LLC

Phase 3

112

Bergamo, Bologna, Florence, Pescara, Roma, San Giovanni Rotondo, Trieste

2024-01-19

Active, closed

A Study of DB-1303/BNT323 vs Investigator's Choice Chemotherapy in HER2-Low, Hormone Receptor Positive Metastatic Breast Cancer (DYNASTY-Breast02)

NCT06018337Metastatic Breast Cancer

DrugsDB-1303/BNT323·Nab-paclitaxel·Capecitabine·Paclitaxel

DualityBio Inc.

Phase 3

541

Bergamo, Brescia, Catania, Catanzaro, Milan, Pavia, Verona, Naples

2024-01-18

Recruiting

A Study to Determine the Efficacy and Safety of Finerenone on Morbidity and Mortality Among Hospitalized Heart Failure Patients

NCT06008197Heart Failure, Acute Heart Failure

DrugsKerendia·Finerenone

Colorado Prevention Center

Phase 3

5,200

Bergamo, Catanzaro, Genova, Varese, Ancona, Brescia

2024-01-17

Recruiting

AZD0486 as Monotherapy in B-cell Acute Lymphoblastic Leukaemia

NCT06137118B-cell Acute Lymphoblastic Leukemia (B-ALL)

DrugSurovatamig

AstraZeneca

Phase 1/2

255

Bergamo, Bologna, Monza, Naples, Roma

2023-12-29

Recruiting

Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥ 50% (MK-2870-007)

NCT06170788Non-small Cell Lung Cancer (NSCLC)

DrugsSacituzumab tirumotecan·Keytruda·Pembrolizumab

Merck Sharp & Dohme LLC

Phase 3

614

Bari, Meldola, Udine, Milan, Bergamo, Catanzaro, Florence, Roma

2023-12-15

Recruiting

Elacestrant for Treating ER+/HER2- Breast Cancer Patients With ctDNA Relapse (TREAT ctDNA)

NCT05512364ER-positive Breast Cancer, HER2-negative Breast Cancer, Stage IIB Breast Cancer, Stage III Breast Cancer

DrugsElacestrant·Tamoxifen·Exemestane·Anastrozole

European Organisation for Research and Treatment of Cancer - EORTC

Phase 3

220

Aviano, Bergamo, Cattolica, Florence, Genova, Guastalla, Lecco, Legnano

2023-12-15

Recruiting

Allogeneic CARCIK-CD19 in Adults/Pediatric B-cell NHL or Chronic Lymphocytic Leukemia

NCT05869279B-cell NHL, CLL

Fondazione Matilde Tettamanti Menotti De Marchi Onlus

Phase 1/2

Bergamo

2023-12-01

Recruiting

A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05)

NCT06103864Breast Cancer

DrugsDato-DXd·Durvalumab·Nab-paclitaxel·Gemcitabine

AstraZeneca

Phase 3

625

Bergamo, Empoli, Milan, Modena, Naples, Padova, Reggio Emilia, Roma

2023-11-23

Active, closed

MEDI5752 in Combination With Carboplatin Plus Pemetrexed in Unresectable Pleural Mesothelioma

NCT06097728Unresectable Pleural Mesothelioma

DrugsVolrustomig·Yervoy·Paraplatin·Ipilimumab

AstraZeneca

Phase 3

863

Alessandria, Bari, Bergamo, Milan, Monza, Orbassano, Padova, Parma

2023-11-09

Recruiting

CisPlatin plUs Gemcitabine and Nabpaclitaxel (GAP) as pReoperative Chemotherapy Versus Immediate Resection in patIents With resecTable BiliarY Tract Cancers (BTC) at High Risk for Recurrence

NCT06037980Biliary Tract Cancer, Cholangiocarcinoma

DrugsAbraxane·Nab-paclitaxel·Capecitabine·Gemcitabine

Gruppo Oncologico del Nord-Ovest

Phase 2/3

300

Ancona, Bergamo, Bologna, Brescia, Cuneo, Meldola, Milan, Modena

2023-11-07

Active, closed

Study to Investigate Efficacy, Safety, and Tolerability of Zibotentan/Dapagliflozin Compared to Dapagliflozin in Participants With Chronic Kidney Disease and High Proteinuria (ZENITH High Proteinuria)

NCT06087835Chronic Kidney Disease With High Proteinuria

DrugDapagliflozin

AstraZeneca

Phase 3

1,835

Bergamo, Bologna, Foggia, Genoa, Naples, Pisa, Roma, Torino

2023-11-07

Active, closed

Study to Evaluate Safety, Tolerability and Drug Levels of BMS-986435/MYK-224 in Participants With Heart Failure With Preserved Ejection Fraction (HFpEF)

NCT06122779Heart Failure

DrugBMS-986435

Bristol-Myers Squibb

Phase 2

227

Naples, San Donato Milanese, Pisa, Bergamo

2023-11-07

Active, closed

A Study to Evaluate Whether Participants With Melanoma Prefer Subcutaneous vs Intravenous Administration of Nivolumab and Nivolumab + Relatlimab Fixed-dose Combinations

NCT06101134Melanoma

DrugsPhesgo·Relatlimab·Opdivo·Nivolumab

Bristol-Myers Squibb

Phase 2

100

Bergamo, Meldola, Milan, Padova, Roma, Torino, Naples

2023-11-06

Active, closed

A Study to Evaluate ABP 206 Compared With OPDIVO® (Nivolumab) in Subjects With Unresectable or Metastatic Melanoma

NCT06054555Melanoma

DrugsOpdivo·Nivolumab

Amgen

Phase 3

633

Crema, Meldola, Taormina, Rozzano, Alessandria, Bari, Bergamo, Florence

2023-11-02

Active, closed

A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Progressive Pulmonary Fibrosis

NCT06025578Progressive Pulmonary Fibrosis

DrugAdmilparant

Bristol-Myers Squibb

Phase 3

1,057

Ancona, Modena, Florence, Milan, Pisa, Roma, Trieste, Bergamo

2023-10-25

Active, closed

A Global Study of Volrustomig (MEDI5752) Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy for Participants With Metastatic Non-small Cell Lung Cancer.

NCT05984277Metastatic Non-small Cell Lung Cancer

DrugsVolrustomig·Pemetrexed·Paclitaxel·Carboplatin

AstraZeneca

Phase 3

895

Bari, Bergamo, Milan, Padova, Parma, Pavia, Ravenna, Roma

2023-10-24

Recruiting

A Study to Evaluate Glofitamab as a Single Agent vs. Investigator's Choice in Participants With Relapsed/Refractory Mantle Cell Lymphoma

NCT06084936Lymphoma

DrugsGlofitamab·Bendamustine·Tocilizumab·Obinutuzumab

Hoffmann-La Roche

Phase 3

182

Bologna, Bergamo, Milan, Alessandria, Turin

2023-10-22

Recruiting

Rescue Stenting and Intravenous Thrombolysis In Patients With Large Vessel Ischemic Stroke

NCT06727006Large Vessel Occlusion, Stroke Acute, Thrombolysis, Rescue Stenting

ASST Santi Paolo e Carlo

Observational

400

Bergamo, Cesena, Lecce, Milan, Monza, Pietra Ligure

2023-10-21

Active, closed

Enlicitide Decanoate (MK-0616 Oral PCSK9 Inhibitor) Cardiovascular Outcomes Study (MK-0616-015) CORALreef Outcomes

NCT06008756Arteriosclerosis, Hypercholesterolaemia

DrugEnlicitide Decanoate

Merck Sharp & Dohme LLC

Phase 3

14,550

Cona, Rome, Bergamo, Brescia, Milan, Monza, Turin, Palermo

2023-10-09

Active, closed

An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2)

NCT05952557Breast Cancer, Early Breast Cancer

DrugsCamizestrant·Tamoxifen·Exemestane·Anastrozole

AstraZeneca

Phase 3

5,511

Bergamo, Bologna, Florence, Genoa, Meldola, Milan, Misterbianco, Monza

2023-10-05

Recruiting

Mesenchymal Stromal Cells for Traumatic Brain Injury

NCT06163833Traumatic Brain Injury With Loss of Consciousness

Fondazione IRCCS San Gerardo dei Tintori

Phase 2

Monza, Bergamo, Milan

2023-09-19

Active, closed

An Open-Label Study Comparing Glofitamab and Polatuzumab Vedotin + Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone Versus Pola-R-CHP in Previously Untreated Patients With Large B-Cell Lymphoma

NCT06047080Large B-Cell Lymphoma

DrugsPolatuzumab Vedotin·Glofitamab·Doxorubicin·Prednisone

Hoffmann-La Roche

Phase 3

1,130

Naples, Bologna, Modena, Genoa, Bergamo, Milan, Rozzano, Catania

2023-09-18

Active, closed

A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Idiopathic Pulmonary Fibrosis

NCT06003426Idiopathic Pulmonary Fibrosis

DrugAdmilparant

Bristol-Myers Squibb

Phase 3

1,255

Bologna, Modena, Florence, Milan, Pisa, Roma, Ancona, Bergamo

2023-09-14

Recruiting

Rescue of Nephrons With ALE.F02 (RENAL-F02)

NCT06047171Glomerulonephritis Rapidly Progressive

DrugsCyclophosphamid·Rituximab

Alentis Therapeutics AG

Phase 2

Bergamo, Florence, Milan, Rome, Trento

2023-09-07

Recruiting

TTFields in General Routine Clinical Care in Patients With Pleural Mesothelioma Study

NCT05538806Pleural Mesothelioma

NovoCure Ltd.

Observational

198

Alessandria, Bergamo

2023-08-01

Active, closed

ONC-392 Versus Docetaxel in Metastatic NSCLC That Progressed on PD-1/PD-L1 Inhibitors

NCT05671510Non Small Cell Lung Cancer

DrugsGotistobart·Taxotere·Docetaxel

OncoC4, Inc.

Phase 3

630

Ancona, Bari, Bergamo, Catania, Milan, Monza, Naples, Palermo

2023-06-28

Active, closed

Study to Evaluate Adverse Events, Change in Disease Activity, and How Oral ABBV-101 Moves Through the Body in Adult Participants With B-Cell Malignancies

NCT05753501Hematologic Cancer

DrugVenetoclax

AbbVie

Phase 1

135

Milan, Turin, Bergamo, Bologna

2023-06-09

Active, closed

A Study of BMS-986449 With and Without Nivolumab in Participants With Advanced Solid Tumors

NCT05888831Advanced Solid Tumors

DrugsOpdivo·Nivolumab

Bristol-Myers Squibb

Phase 1/2

100

Rozzano, Siena, Bergamo, Roma

2023-06-06

Active, closed

Study Comparing Tarlatamab With Standard of Care Chemotherapy in Relapsed Small Cell Lung Cancer

NCT05740566Small Cell Lung Cancer (SCLC)

DrugsAmrubicin·Lurbinectedin·Tarlatamab·Topotecan

Amgen

Phase 3

509

Bergamo, Catanzaro, Genova, Meldola (FC), Orbassano, Roma

2023-05-31

Recruiting

Acoustic Analysis of VA Sounds

NCT05612022End Stage Renal Disease, Hemodialysis Access Failure

Mario Negri Institute for Pharmacological Research

Observational

Bergamo

2023-05-09

Active, closed

Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Patients With Hormone Receptor-positive/Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Metastatic Breast Cancer Who Have Received Endocrine Therapy

NCT05840211Locally Advanced or Unresectable Metastatic Breast Cancer, Stage IV Breast Cancer

DrugsAbraxane·Xeloda·Sacituzumab Govitecan·Taxol

Gilead Sciences

Phase 3

654

Ancona AN, Aviano, Bergamo, Bologna, Catania, Catanzaro, Genova GE, Milan

2023-05-08

Recruiting

Comparison of the Outcomes of Single vs Multiple Arterial Grafts in Women

NCT04124120Heart Diseases, Coronary Artery Disease, Coronary Artery Bypass Grafting

Weill Medical College of Cornell University

Not applicable

2,300

Bari, Bergamo, Brescia, Cotignola, Florence, Roma, Torino

2023-04-17

Active, closed

A Study of Milvexian Versus Apixaban in Participants With Atrial Fibrillation

NCT05757869Atrial Fibrillation

DrugsMilvexian·Apixaban

Janssen Research & Development, LLC

Phase 3

20,284

Arezzo, Aversa, Bergamo, Bologna, Caserta, Catania, Catanzaro, Ferrara

2023-04-11

Active, closed

Study of Pembrolizumab (MK-3475) Monotherapy Versus Sacituzumab Govitecan in Combination With Pembrolizumab for Participants With Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-3475-D46)

NCT05609968Carcinoma, Non-Small-Cell Lung

DrugsSacituzumab Govitecan·Keytruda·Pembrolizumab

Merck Sharp & Dohme LLC

Phase 3

614

Rome, Bergamo, Milan, Naples, Florence, Peschiera del Garda, Parma

2023-02-06

Active, closed

Study of ONCOFID-P-B (PACLITAXEL-HYALURONIC ACID)

NCT05024773Bladder Carcinoma in Situ (CIS)

Fidia Farmaceutici s.p.a.

Phase 3

130

Bergamo, Bologna, Castelfranco Veneto, Florence, Lecce, Milan, Naples, Roma

2022-12-29

Recruiting

Restoring Sensitivity To Immunotherapy In Advanced Triple Negative Breast Cancer Exploiting Ceralasertib Priming Followed By Combined Durvalumab/Nab-Paclitaxel

NCT05582538Triple Negative Breast Cancer Metastatic

DrugsCeralasertib·Abraxane·Durvalumab·Nab-paclitaxel

IFOM ETS - The AIRC Institute of Molecular Oncology

Phase 2

Novara, Bergamo, Milan, Naples, Padova, Reggio Emilia

2022-12-15

Active, closed

CORE-OLE: A Study of Olezarsen (ISIS 678354) Administered Subcutaneously to Participants With Severe Hypertriglyceridemia (SHTG)

NCT05681351Severe Hypertriglyceridemia

DrugOlezarsen

Ionis Pharmaceuticals, Inc.

Phase 3

885

Bergamo, Bologna, Caserta, Milan, Naples, Palmero, Rome

2022-12-13

Recruiting

Neurosurgical Outcome Network

NCT06724029Aneurysms, Arteriovenous Malformations, Cavernomas, Skull Base Tumors

Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta

Observational

4,500

Bergamo, Brescia, Gravedona, Como, Cremona, Monza, Pavia, Sondrio

2022-12-05

Active, closed

Safety and Efficacy of ALXN1720 in Adults With Generalized Myasthenia Gravis

NCT05556096Generalized Myasthenia Gravis

Alexion Pharmaceuticals, Inc.

Phase 3

260

Bergamo, Brescia, Florence, Milan, Naples, Palermo, Pisa, Roma

2022-11-21

Active, closed

A Real-World Study to Gain Clinical Insights Into Roche Ophthalmology Products

NCT05476926Neovascular Age-related Macular Degeneration, Diabetic Macular Edema, Retinal Vein Occlusion, Branch Retinal Vein Occlusion

DrugsVabysmo·Faricimab

Hoffmann-La Roche

Observational

6,000

Chieti, Bari, Catanzaro, Naples, Udine, Rome, Genoa, Bergamo

2022-11-21

Recruiting

A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma

NCT05552222Multiple Myeloma

DrugsTalquetamab·Teclistamab·Daratumumab·Lenalidomide

Janssen Research & Development, LLC

Phase 3

1,590

Bergamo, Bologna, Florence, Milan, Naples, Pavia, Roma, Rozzano

2022-10-25

Recruiting

National Database on Primary Sclerosing Cholangitis (PSC)

NCT05618145Primary Sclerosing Cholangitis

University of Milano Bicocca

Observational

6,000

Ancona, Bari, Bergamo, Bologna, Bolzano, Brescia, Cagliari, Castellana Grotte

2022-10-21

Active, closed

A Study Evaluating the Efficacy and Safety of Cevostamab in Prior B Cell Maturation Antigen (BCMA)-Exposed Participants With Relapsed/Refractory Multiple Myeloma

NCT05535244Multiple Myeloma

DrugsCevostamab·Tocilizumab

Hoffmann-La Roche

Phase 1/2

Bologna, Bergamo, Milan, Turin

2022-10-17

Active, closed

A Platform Study of Novel Immunotherapy Combinations in Participants With Previously Untreated, Advanced/Metastatic Non-Small-Cell Lung Cancer

NCT05565378Lung Cancer, Non-Small Cell

DrugsNelistotug·Belrestotug·Dostarlimab·Pembrolizumab

GlaxoSmithKline

Phase 2

351

Avellino, Bergamo, Genova, Pisa, Verona

2022-10-14

Active, closed

Ponatinib Plus Chemotherapy in Acute Lymphoblastic Leukemia Patients

NCT05306301Chemotherapy, Leukemia, Acute Lymphoblastic

DrugPonatinib

Gruppo Italiano Malattie EMatologiche dell'Adulto

Phase 2

Avellino, Pagani, Bergamo, Bologna, Brescia, Catania, Florence, Lecce

2022-10-05

Active, closed

A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer

NCT05514054Breast Neoplasms

DrugsImlunestrant·Tamoxifen·Exemestane·Anastrozole

Eli Lilly and Company

Phase 3

8,000

Ancona, Bergamo, Bologna, Brindisi, Candiolo, Florence, Genova, Milan

2022-10-04

Active, closed

Study of Axicabtagene Ciloleucel Versus Standard of Care Therapy in Participants With Relapsed/Refractory Follicular Lymphoma

NCT05371093Relapsed/Refractory Follicular Lymphoma

DrugsAxi-cel·Axicabtagene Ciloleucel·Bendamustine·Vincristine

Kite, A Gilead Company

Phase 3

231

Bergamo, Bologna, Milan, Reggio Emilia, Rozzano

2022-09-22

Recruiting

Observational Study on the Use of Ropeginterferon Alfa-2b in Polycythemia Vera (ROPEG-PV)

NCT06506084Polycythemia Vera

DrugBesremi

FROM- Fondazione per la Ricerca Ospedale di Bergamo- ETS

Observational

429

Bergamo, Milan, Pavia, Varese, Padova, Verona, Vicenza, Alessandria

2022-09-08

Recruiting

EPOS Discoid Meniscus (DiMe) Project

NCT05580315Discoid Meniscus of Knee

University of Milano Bicocca

Observational

500

Bergamo, Monza

2022-09-08

Recruiting

Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation

NCT05243797Multiple Myeloma

DrugsTeclistamab·Lenalidomide

European Myeloma Network B.V.

Phase 3

1,594

Alessandria, Ancona, Bari, Bergamo, Bologna, Brescia, Cagliari, Cosenza

2022-09-08

Recruiting

The Medacta GMK SpheriKA Post-Marketing Surveillance Study

NCT05459948Arthropathy, Knee Replacement

Medacta International SA

Observational

281

Bergamo

2022-07-30

Recruiting

Comparison Of Reduced DAPT Followed by P2Y12 Inhibitor Monotherapy With Prasugrel vs stAndard Regimen in STEMI Patients

NCT05491200ST Elevated Myocardial Infarction, Dual Antiplatelet Therapy

Research Maatschap Cardiologen Rotterdam Zuid

Phase 4

1,656

Bergamo, Ferrara, Genova, Milan, Naples, Roma

2022-07-22

Recruiting

The Italian Transthyretin Amyloidosis Web-Network

NCT05444920ATTR Amyloidosis

Fondazione IRCCS Policlinico San Matteo di Pavia

Observational

1,000

Legnano, Orbassano, Ancona, Bari, Bergamo, Brescia, Cagliari, Cosenza

2022-07-13

Active, closed

An Open-label Extension Study to Evaluate Long-term Efficacy and Safety of Odevixibat in Children With Biliary Atresia

NCT05426733Biliary Atresia

DrugOdevixibat

Albireo, an Ipsen Company

Phase 3

180

Bergamo, Padova

2022-07-05

Recruiting

Efficacy of Atenativ in Patients With Congenital Antithrombin Deficiency Undergoing Surgery or Delivery

NCT04918173Congenital Antithrombin Deficiency

Octapharma

Phase 3

Bergamo, Milan, Padua, Roma

2022-07-01

Active, closed

A Study to Evaluate the Safety and Anti-cancer Activity of Loncastuximab Tesirine in Combination With Other Anti-cancer Agents in Participants With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (LOTIS-7)

NCT04970901B-Cell Non-Hodgkin Lymphoma, Relapsed B-Cell Non-Hodgkin Lymphoma, Refractory B-Cell Non-Hodgkin Lymphoma

DrugsLoncastuximab Tesirine·Mosunetuzumab·Polatuzumab Vedotin·Glofitamab

ADC Therapeutics S.A.

Phase 1

154

Bergamo, Bologna, Brescia, Milan

2022-06-17

Active, closed

Adjuvant Encorafenib and Binimetinib in High-risk Stage II Melanoma With a BRAF Mutation.

NCT05270044Melanoma

Pierre Fabre Medicament

Phase 3

815

Meldola, Taormina, Naples, Aviano, Bari, Bergamo, Cuneo, Genova

2022-05-02

Active, closed

A Phase 3 Study of Rusfertide in Patients With Polycythemia Vera

NCT05210790Polycythemia Vera

DrugRusfertide

Protagonist Therapeutics, Inc.

Phase 3

293

Meldola, Bergamo, Bologna, Brescia, Florence, Milan, Pavia, Pesaro

2022-04-01

Active, closed

A Global Study to Assess the Effects of Durvalumab + Domvanalimab Following Concurrent Chemoradiation in Participants With Stage III Unresectable NSCLC

NCT05211895Non-Small Cell Lung Cancer

DrugsDomvanalimab·Durvalumab

AstraZeneca

Phase 3

791

Bergamo, Roma, Rozzano

2022-02-18

Recruiting

Italian Anderson Fabry Disease Cardiovascular Registry

NCT06806813Fabry Disease

IRCCS Azienda Ospedaliero-Universitaria di Bologna

Observational

800

Chieti, Potenza, Caserta, Catanzaro, Cosenza, Bologna, Genova, Bergamo

2022-01-26

Recruiting

Severe Acquired Brain Injuries: Prognostic Factors and Quality of Care

NCT04905264Brain Injuries, Acute

Mario Negri Institute for Pharmacological Research

Observational

2,500

Alessandria, Arezzo, Baggiovara, Bergamo, Bologna, Brescia, Cagliari, Correggio

2022-01-03

Active, closed

Study to Assess the Efficacy and Safety of Alpelisib Plus Fulvestrant in Participants With HR-positive (HR+), HER2-negative, Advanced Breast Cancer After Treatment With a CDK4/6 Inhibitor and an Aromatase Inhibitor.

NCT05038735Breast Cancer

DrugsAlpelisib·Fulvestrant

Novartis Pharmaceuticals

Phase 3

210

Bari, Bergamo, Bologna, Florence, Genova, Milan, Rozzano, Palermo

2021-12-17

Active, closed

A Study to Test How Safe Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Alone Are and How Well They Work in Adult Patients With Generalized Myasthenia Gravis

NCT05070858Generalized Myasthenia Gravis

DrugsCemdisiran·Pozelimab

Regeneron Pharmaceuticals

Phase 3

288

Rome, Milan, Pisa, Bergamo, Roma

2021-12-14

Active, closed

Long-term Follow-up Study to Evaluate Durability of Treatment Response in Previous Bepirovirsen Study Participants (B-Sure)

NCT04954859Hepatitis B

DrugBepirovirsen

GlaxoSmithKline

Phase 2

360

Bergamo, Milan, Modena, Naples, Palermo, Pisa

2021-12-14

Active, closed

Trial in AML Secondary to MPNs Patients, Unfit for Intensive Chemotherapy, Investigating a Treatment Combination Including Decitabine and Venetoclax

NCT04763928Acute Myeloid Leukemia

DrugsDecitabine·Venetoclax

Gruppo Italiano Malattie EMatologiche dell'Adulto

Phase 2

101

Alessandria, Ancona, Bari, Bergamo, Bologna, Brescia, Cagliari, Castelfranco Veneto

2021-12-03

Active, closed

Evaluation of the Quality of Care in the Emergency Department by Studying the Appropriateness of Admissions of Patients Accessing the Emergency Department (ASST Papa Giovanni XXIII)

NCT06345378Quality of Care, Evaluation, Emergency Departments, Appropriateness

Mario Negri Institute for Pharmacological Research

Observational

1,200

Bergamo

2021-11-25

Active, closed

Study of Sacituzumab Govitecan (SG) Versus Docetaxel in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

NCT05089734Non-Small Cell Lung Cancer

DrugsSacituzumab Govitecan·Docetaxel

Gilead Sciences

Phase 3

603

Bergamo, Brescia, Catania, Catanzaro, Cremona, Milan, Pavia, Roma

2021-11-17

Active, closed

Study Comparing Blinatumomab Alternating With Low-intensity Chemotherapy Versus Standard of Care Chemotherapy for Older Adults With Newly Diagnosed Philadelphia-negative B-cell Precursor Acute Lymphoblastic Leukemia

NCT04994717Newly Diagnosed Philadelphia (Ph)-Negative B-cell Precursor Acute Lymphoblastic Leukemia (ALL)

DrugBlinatumomab

Amgen

Phase 3

303

Bari, Bergamo, Bologna, Genova, Lecce, Mestre (VE), Milan, Naples

2021-11-02

Active, closed

A Study of Teclistamab in Combination With Daratumumab Subcutaneously (SC) (Tec-Dara) Versus Daratumumab SC, Pomalidomide, and Dexamethasone (DPd) or Daratumumab SC, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma

NCT05083169Multiple Myeloma

DrugsTeclistamab·Pomalidomide·Bortezomib·Daratumumab

Janssen Research & Development, LLC

Phase 3

587

Bari, Bergamo, Bologna, Florence, Meldola, Pavia, Roma, Turin

2021-10-14

Recruiting

MYTHS - MYocarditis THerapy With Steroids

NCT05150704Myocarditis Acute

DrugMethylprednisolone

Niguarda Hospital

Phase 3

288

Ancona, Bergamo, Bologna, Brescia, Cagliari, Chieti, Florence, Genova

2021-10-07

Active, closed

A Study of Pirtobrutinib (LOXO-305) Versus Bendamustine Plus Rituximab (BR) in Untreated Patients With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

NCT05023980Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma

DrugsRiabni·Ruxience·Truxima·Pirtobrutinib

Loxo Oncology, Inc.

Phase 3

282

Rionero in Vulture, Bergamo, Brescia, Meldola, Milan, Monza, Novara, Perugia

2021-09-23

Active, closed

A Study to Evaluate Efficacy and Safety of an Investigational Drug Named Volixibat in Patients With Itching Caused by Primary Biliary Cholangitis

NCT05050136Primary Biliary Cholangitis, PBC

DrugVolixibat

Mirum Pharmaceuticals, Inc.

Phase 2

333

Ancona, Bergamo, Milan, Modena, Monza, Padova, Palermo, Pisa

2021-09-22

Active, closed

Sequential Treatment With Ponatinib and Blinatumomab vs Chemotherapy and Imatinib in Newly Diagnosed Adult Ph+ ALL

NCT04722848Acute Lymphoblastic Leukemia (Philadelphia Chromosome Positive), ALL, Adult, Philadelphia-Positive ALL

DrugsPonatinib·Imatinib·Blinatumomab

Gruppo Italiano Malattie EMatologiche dell'Adulto

Phase 3

236

Ascoli Piceno, Bari, Bergamo, Bolzano, Brescia, Mestre, Modena, Pagani

2021-09-08

Active, closed

Evaluation of Oral Tofacitinib in Children Aged 2 to 17 Years Old Suffering From Moderate to Severe Ulcerative Colitis

NCT04624230Ulcerative Colitis

DrugTofacitinib

Pfizer

Phase 3

118

Bergamo, Naples, Roma, Bologna

2021-08-12

Recruiting

A Study Evaluating the Safety, Pharmacokinetics, and Activity of Cevostamab in Participants With Relapsed or Refractory Multiple Myeloma

NCT04910568Multiple Myeloma

DrugsCevostamab·Pomalidomide·Tocilizumab·Daratumumab

Genentech, Inc.

Phase 1

186

Bergamo, Brescia

2021-07-26

Recruiting

European and North Indian Cohort of KaWasaki dIsease

NCT06305611Kawasaki Disease

Meyer Children's Hospital IRCCS

Observational

103

Bergamo, Brescia, Florence, Genova, Milan, Palermo, Torino, Trieste

2021-07-13

Recruiting

Liver Transplantation in Patients With CirrHosis and Severe Acute-on-Chronic Liver Failure: iNdications and outComEs

NCT04613921Liver Diseases, Liver Cirrhosis, Acute-On-Chronic Liver Failure, Liver Transplant; Complications

European Foundation for Study of Chronic Liver Failure

Observational

3,000

Bergamo, Bologna, Milan, Padova

2021-07-08

Active, closed

Interventional Strategy for Non-culprit Lesions With Major Vulnerability Criteria at OCT in Patients With ACS

NCT05027984Coronary Artery Disease, Coronary Disease, Ischemic Heart Disease

Centro per la Lotta Contro l'Infarto - Fondazione Onlus

Not applicable

1,425

Ascoli Piceno, Acquaviva delle Fonti, Bari, Bergamo, Benevento, Bologna, Cagliari, Aversa

2021-06-30

Active, closed

Phase III Study to Assess AZD9833+ CDK4/6 Inhibitor in HR+/HER2-MBC With Detectable ESR1m Before Progression (SERENA-6)

NCT04964934ER-Positive HER2-Negative Breast Cancer

DrugsCamizestrant·Anastrozole·Abemaciclib·Ribociclib

AstraZeneca

Phase 3

315

Bergamo, Bologna, Florence, Meldola, Milan, Misterbianco, Naples, Padova

2021-06-30

Active, closed

Assessing a ctDNA and PET-oriented Therapy in Patients With DLBCL A Multicenter, Open-label, Phase II Trial.

NCT04604067Diffuse Large B-cell Lymphoma

DrugAcalabrutinib

Swiss Cancer Institute

Phase 2

260

Bergamo, Novara, Roma

2021-06-25

Active, closed

A Study of T-DXd in Participants With or Without Brain Metastasis Who Have Previously Treated Advanced or Metastatic HER2 Positive Breast Cancer

NCT04739761Breast Cancer

DrugTrastuzumab deruxtecan

AstraZeneca

Phase 3

506

Ancona, Bergamo, Catania, Milan, Naples, Padova, Prato

2021-06-22

Active, closed

Valemetostat Tosylate (DS-3201b), an Enhancer of Zeste Homolog (EZH) 1/2 Dual Inhibitor, for Relapsed/Refractory Peripheral T-Cell Lymphoma (VALENTINE-PTCL01)

NCT04703192Relapsed/Refractory Peripheral T-Cell Lymphoma, Adult T Cell Leukemia/Lymphoma

DrugValemetostat Tosylate

Daiichi Sankyo

Phase 2

155

Bergamo, Bologna, Monza, Naples, Perugia

2021-06-03

Recruiting

A Master Protocol (AMAZ): A Study of Mirikizumab (LY3074828) in Pediatric Participants With Ulcerative Colitis or Crohn's Disease (SHINE-ON)

NCT04844606Ulcerative Colitis, Ulcerative Colitis Chronic, Inflammatory Bowel Diseases, Crohn's Disease

DrugMirikizumab

Eli Lilly and Company

Phase 3

150

Bergamo, Bologna, Florence, Milan, Roma, Rome

2021-05-26

Recruiting

Poor Grade Aneurysmal Subarachnoid Hemorrhage Study Group

NCT04945603Subarachnoid Hemorrhage, Aneurysmal, Poor Grade Subarachnoid Hemorrhage

IRCCS San Raffaele

Observational

800

Bergamo, Bologna, Brescia, Lecce, Milan, Novara, Parma, Roma

2021-05-25

Active, closed

Tafasitamab + Lenalidomide + R-CHOP Versus R-CHOP in Newly Diagnosed High-intermediate and High Risk DLBCL Patients

NCT04824092Diffuse Large B-cell Lymphoma

DrugsTafasitamab·Vincristine·Doxorubicin·Prednisone

Incyte Corporation

Phase 3

899

Bergamo, Brescia, Candiolo, Catania, Forlì, Genoa, Lecce, Milan

2021-05-11

Active, closed

Ponatinib in Adult Ph+ ALL Patients With MRD Positivity or Hematological Relapse

NCT04475731Philadelphia-Positive ALL, Acute Lymphoblastic Leukemia, in Relapse

DrugPonatinib

Gruppo Italiano Malattie EMatologiche dell'Adulto

Phase 2

Ancona, Ascoli Piceno, Avellino, Bari, Bergamo, Bologna, Brescia, Cuneo

2021-05-04

Active, closed

Trastuzumab Deruxtecan (T-DXd) With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive Metastatic Breast Cancer (DESTINY-Breast09)

NCT04784715Breast Cancer; HER2-positive; Metastatic

DrugsPertuzumab·Trastuzumab deruxtecan·Trastuzumab

AstraZeneca

Phase 3

1,157

Bergamo, Candiolo, Genova, Livorno, Milan, Naples, Padova, Rozzano

2021-04-26

Active, closed

A Study of TAK-755 in Participants With Congenital Thrombotic Thrombocytopenic Purpura

NCT04683003Thrombotic Thrombocytopenic Purpura (TTP)

DrugTAK-755

Takeda

Phase 3

Bergamo

2021-04-14

Active, closed

Phase 3 Study of Pelabresib (CPI-0610) in Myelofibrosis (MF) (MANIFEST-2)

NCT04603495Myelofibrosis, Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis

DrugsPelabresib·Ruxolitinib

Novartis Pharmaceuticals

Phase 3

430

Bergamo, Bologna, Brescia, Ferrara, Florence, Meldola, Milan, Monza

2021-04-09

Active, closed

A Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared With Teriflunomide in Relapsing Multiple Sclerosis (RMS)

NCT04586010Relapsing Multiple Sclerosis

DrugsFenebrutinib·Teriflunomide

Hoffmann-La Roche

Phase 3

746

Foggia, Naples, Parma, Rome, Bergamo, Milan, Mondovì (CN), Catania

2021-03-17

Active, closed

Study of LOXO-305 (Pirtobrutinib) Versus Investigator's Choice (Idelalisib Plus Rituximab or Bendamustine Plus Rituximab) in Patients With Previously Treated Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

NCT04666038Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma

DrugsIdelalisib·Truxima·Pirtobrutinib·Bendamustine

Loxo Oncology, Inc.

Phase 3

238

Viale Orazio Flacco, Monza (MB) -Settore E, Pisa, Rionero in Vulture, Vicenza, Alessandria, Bergamo, Brescia

2021-03-09

Active, closed

Neoadjuvant Plus Adjuvant Treatment With Cemiplimab in Cutaneaous Squamous Cell Carcinoma

NCT04632433Cutaneous Squamous Cell Carcinoma

DrugCemiplimab

Fondazione Melanoma Onlus

Phase 2

Bergamo, Bagno a Ripoli, Meldola, Milan, Naples, Padova, Brescia

2021-02-10

Recruiting

Metabolic Exercise Test Data Combined with Cardiac and Kidney Indexes (MECKI) Score Evolution: Identification of Cardiovascular Risk in Patients with Heart Failure

NCT06884631Heart Failure

Centro Cardiologico Monzino

Observational

10,000

Milan, Ancona, Bari, Bergamo, Brescia, Foggia, Naples, Palermo

2021-02-10

Recruiting

SCAD : a Registry of Spontaneous Coronary Artery Dissection

NCT06601270Spontaneous Coronary Artery Dissection

European Society of Cardiology

Observational

1,500

Bergamo, Foggia, Genoa, Mantua, Milan, Monza

2021-01-30

Active, closed

A Comparative Study of AZD9833 Plus Palbociclib Versus Anastrozole Plus Palbociclib in Patients With ER-Positive HER2 Negative Breast Cancer Who Have Not Received Any Systemic Treatment for Advanced Disease

NCT04711252ER-Positive HER2-Negative Breast Cancer

DrugsCamizestrant·Anastrozole·Palbociclib

AstraZeneca

Phase 3

1,371

Bergamo, Florence, Milan, Modena, Naples, Novara, Padova, Parma

2021-01-28

Active, closed

A Phase 3 Trial of Epcoritamab vs Investigator's Choice Chemotherapy in Relapsed/Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL)

NCT04628494Diffuse Large B-cell Lymphoma

DrugEpcoritamab

Genmab

Phase 3

483

Bari, Bergamo, Brescia, Meldola, Milan, Novara, Pavia, Ravenna

2021-01-13

Active, closed

A Study of Subcutaneous Blinatumomab Administration in Participants With R/R and MRD+ B-ALL

NCT04521231B Cell Precursor Acute Lymphoblastic Leukemia

DrugBlinatumomab

Amgen

Phase 1/2

181

Bergamo, Bologna, Brescia, Catania, Milan, Naples, Roma

2021-01-04

Active, closed

Safety and Efficacy Trial of Epcoritamab Combinations in Subjects With B-cell Non-Hodgkin Lymphoma (B-NHL)

NCT04663347Diffuse Large B-Cell Lymphoma, Follicular Lymphoma

DrugsR-Ice·Rituximab and lenalidomide·Gemcitabine and oxaliplatin·Epcoritamab

Genmab

Phase 1/2

543

Bergamo, Bologna, Candiolo, Meldola, Milan, Pavia, Reggio Emilia

2020-11-03

Active, closed

Short-course Versus Long-course Pre-operative Chemotherapy With mFOLFIRINOX or PAXG (CASSANDRA TRIAL)

NCT04793932Pancreas Ductal Adenocarcinoma

DrugMFOLFIRINOX

Associazione Italiana per lo Studio del Pancreas

Phase 3

261

Aviano, Bari, Bergamo, Bologna, Brescia, Florence, Meldola, Milan

2020-11-03

Active, closed

A Combination of Acalabrutinib With R-CHOP in Subjects With Previously Untreated Non-GCB DLBCL (ACE-LY-312)

NCT04529772Diffuse Large B-Cell Lymphoma

DrugsAcalabrutinib·Vincristine·Doxorubicin·Prednisone

Acerta Pharma BV

Phase 3

611

Bari, Bergamo, Bologna, Florence, Genova, Meldola, Milan, Novara

2020-10-08

Active, closed

A Study of Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma

NCT04557098Hematological Malignancies

DrugTeclistamab

Janssen Research & Development, LLC

Phase 2

194

Bergamo, Bologna, Milan

2020-09-17

Active, closed

A Phase 1 Trial of ZN-A-1041 Enteric Capsules or Combination in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Advanced Solid Tumors

NCT05593094Advanced Solid Tumors, HER2-positive Breast Cancer

DrugZN-A-1041

Hoffmann-La Roche

Phase 1/2

210

Parma, Bergamo, Magnago

2020-09-03

Active, closed

Study of Oral Navitoclax Tablet in Combination With Oral Ruxolitinib Tablet Versus Best Available Therapy to Assess Change in Spleen Volume in Adult Participants With Relapsed/Refractory Myelofibrosis

NCT04468984Myelofibrosis (MF)

DrugsNavitoclax·Ruxolitinib

AbbVie

Phase 3

330

Bologna, Florence, Rome, Monza, Naples, Turin, Ancona, Bergamo

2020-08-31

Active, closed

Study of Trastuzumab Deruxtecan (T-DXd) vs Investigator's Choice Chemotherapy in HER2-low, Hormone Receptor Positive, Metastatic Breast Cancer

NCT04494425Advanced or Metastatic Breast Cancer

DrugsTrastuzumab deruxtecan·Nab-paclitaxel·Capecitabine·Paclitaxel

AstraZeneca

Phase 3

866

Aviano, Bergamo, Candiolo, Cona, Genova, Livorno, Messina, Milan

2020-07-24

Recruiting

A Master Protocol Empowering Mechanobiology Translation Research in Breast Cancer

NCT04625023Breast Cancer

IFOM ETS - The AIRC Institute of Molecular Oncology

Observational

1,500

Bergamo, Milan, Novara, Padova, Pavia, Roma, Reggio Emilia

2020-07-16

Active, closed

A Study to Evaluate the Efficacy and Safety of JCAR017 in Adult Subjects With Relapsed or Refractory Indolent B-cell Non-Hodgkin Lymphoma (NHL)

NCT04245839Lymphoma, Non-Hodgkin

DrugsLiso-cel·Fludarabine·Cyclophosphamide

Celgene

Phase 2

276

Bergamo, Naples

2020-07-14

Active, closed

Evaluation of Efficacy and Safety of Belantamab Mafodotin, Bortezomib and Dexamethasone Versus Daratumumab, Bortezomib and Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma

NCT04246047Multiple Myeloma

DrugsBelantamab mafodotin·Bortezomib·Daratumumab·Dexamethasone

GlaxoSmithKline

Phase 3

494

Bergamo, Meldola FC, Milan, Siena

2020-05-07

Active, closed

Capivasertib+Fulvestrant vs Placebo+Fulvestrant as Treatment for Locally Advanced (Inoperable) or Metastatic HR+/HER2- Breast Cancer

NCT04305496Locally Advanced (Inoperable) or Metastatic Breast Cancer

DrugsCapivasertib·Fulvestrant

AstraZeneca

Phase 3

818

Bergamo, Candiolo, Catanzaro, Livorno, Meldola, Milan, Modena, Naples

2020-04-16

Recruiting

Comprehensive Aneurysm Management Trial

NCT04155606Saccular Aneurysm, Intracranial Aneurysm, Unruptured Cerebral Aneurysm

Centre hospitalier de l'Université de Montréal (CHUM)

Not applicable

2,000

Bergamo, Lecce, Milan

2020-01-15

Active, closed

Study to Evaluate the Safety and Efficacy of Lenacapavir (GS-6207) in Combination With an Optimized Background Regimen (OBR) in Heavily Treatment Experienced Participants Living With HIV-1 Infection With Multidrug Resistance

NCT04150068HIV-1-infection

DrugLenacapavir

Gilead Sciences

Phase 2/3

Bergamo, Brescia, Milan, Roma, Rome

2019-11-21

Active, closed

NCT04232241Acute Myeloid Leukemia in Remission, Acute Lymphoblastic Leukemia in Remission, Myelodysplastic Syndromes

Universitätsklinikum Hamburg-Eppendorf

Phase 2

167

Bergamo

2019-11-14

Active, closed

Feasibility and Effectiveness of Inotuzumab Ozogamicin in B-Cell Acute Lymphoblastic Leukemia

NCT03610438Acute Lymphoid Leukemia

DrugInotuzumab Ozogamicin

Gruppo Italiano Malattie EMatologiche dell'Adulto

Phase 2

Ancona, Ascoli Piceno, Bergamo, Bologna, Bolzano, Brescia, Cuneo, Genova

2019-10-30

Active, closed

Effectiveness Study of Nivolumab Compared to Placebo in Prevention of Recurrent Melanoma After Complete Resection of Stage IIB/C Melanoma

NCT04099251Melanoma

DrugsOpdivo·Nivolumab

Bristol-Myers Squibb

Phase 3

790

Palermo, Bergamo, Milan, Naples, Padova, Perugia, Siena

2019-10-28

Active, closed

Prospective Observational Study of Adjuvant Hormone Treatment in Estrogen-receptor Positive Premenopausal Early Breast Cancer Patients

NCT05730647Early Breast Cancer

Consorzio Oncotech

Observational

600

Aviano, Bari, Bergamo, Brindisi, Chieti, Como, Cuneo, Florence

2019-10-24

Recruiting

Treatment Study for Children and Adolescents With Acute Promyelocytic Leukemia

NCT04793919Acute Promyelocytic Leukemia

DrugsMylotarg·All-trans retinoic acid·Arsenic Trioxide·ATRA

Associazione Italiana Ematologia Oncologia Pediatrica

Phase 2

San Giovanni Rotondo, Bari, Bergamo, Bologna, Cagliari, Catania, Florence, Genova

2019-10-09

Active, closed

ObinutuzuMab AtezOlizumab and VenetocLax in RichTer transfOrmation

NCT04082897CLL Transformation

DrugsTecentriq·Obinutuzumab·Atezolizumab·Venetoclax

Niguarda Hospital

Phase 2

Alessandria, Bergamo, Bologna, Brescia, Milan, Novara, Pavia, Roma

2019-10-04

Recruiting

National Database on Primary Biliary Cholangitis

NCT05151809Primary Biliary Cholangitis

University of Milano Bicocca

Observational

6,000

Ancona, Bari, Bergamo, Bologna, Bolzano, Brescia, Cagliari, Castellana Grotte

2019-09-19

Active, closed

Palbociclib for HR Positive / HER2-negative Isolated Locoregional Recurrence of Breast Cancer

NCT03820830Breast Cancer Recurrent

DrugPalbociclib

ETOP IBCSG Partners Foundation

Phase 3

405

Aviano, Bergamo, Brindisi, Meldola, Milan, Novara, Parma, Pavia

2019-08-27

Recruiting

International Cooperative Treatment Protocol for Children and Adolescents With Lymphoblastic Lymphoma

NCT04043494Lymphoblastic Lymphoma, Childhood

DrugsVindesine·Thioguanine·PEG-Asparaginase·Ifosfamide

University Hospital Muenster

Phase 3

683

Ancona, Bari, Bergamo, Bologna, Brescia, Cagliari, Catania, Cona

2019-08-23

Active, closed

A Study to Evaluate the Safety, Pharmacokinetics and Preliminary Anti-Tumor Activity of Englumafusp Alfa in Combination With Obinutuzumab and in Combination With Glofitamab Following a Pre-Treatment Dose of Obinutuzumab in Participants With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma

NCT04077723Lymphoma, Non-Hodgkin

DrugsGlofitamab·Tocilizumab·Obinutuzumab

Hoffmann-La Roche

Phase 1/2

498

Naples, Bergamo, Milan, Rozzano

2019-08-13

Recruiting

Pan Tumor Rollover Study

NCT03899155Cancer

DrugsRucaparib·Sunitinib·Trametinib·Relatlimab

Bristol-Myers Squibb

Phase 2

1,500

Meldola, Rozzano, Roma, Bari, Bergamo, Candiolo, Catania, Genova

2019-08-09

Active, closed

Postoperative Immunotherapy vs Standard Chemotherapy for Gastric Cancer With High Risk for Recurrence

NCT03443856Gastric and Esophagogastric Junction Adenocarcinoma

DrugNivolumab and Ipilimumab

European Organisation for Research and Treatment of Cancer - EORTC

Phase 2

197

Bergamo, Milan, Naples

2019-07-17

Active, closed

A Trial for Relapsed and Relapsed/Refractory Multiple Myeloma Patients

NCT04124497Multiple Myeloma, Deletion 17P Syndrome

DrugsDarzalex·Pomalidomide·Daratumumab·Dexamethasone

Fondazione EMN Italy Onlus

Phase 2

Ancona, Bari, Bergamo, Bologna, Brescia, Catania, Milan, Novara

2019-07-01

Active, closed

A Trial That Compare Two Treatments in Newly Diagnosed Myeloma Patients Not Eligible for Transplant

NCT04096066Multiple Myeloma, New Diagnosis Tumor

DrugsCarfilzomib·Lenalidomide·Dexamethasone

Fondazione EMN Italy Onlus

Phase 3

Alessandria, Ancona, Ascoli Piceno, Bari, Bergamo, Bolzano, Brescia, Cagliari

2019-07-01

Active, closed

Phase I/II Study of Rapcabtagene Autoleucel in CLL, 3L+ DLBCL, r/r ALL and 1L HR LBCL

NCT03960840Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Diffuse Large B-cell Lymphoma, Acute Lymphoblastic Leukemia

DrugIbrutinib

Novartis Pharmaceuticals

Phase 1/2

217

Bergamo, Milan, Rozzano

2019-06-26

Active, closed

Study of Adjuvant Cemiplimab Versus Placebo After Surgery and Radiation Therapy in Patients With High Risk Cutaneous Squamous Cell Carcinoma

NCT03969004Cutaneous Squamous Cell Carcinoma

DrugCemiplimab

Regeneron Pharmaceuticals

Phase 3

415

Bergamo, Bologna, Brescia, Florence, L’Aquila, Milan, Naples, Rome

2019-06-04

Active, closed

A Safety and Preliminary Efficacy Study of CC-99282, Alone and in Combination With Anti-lymphoma Agents in Participants With Relapsed or Refractory Non-Hodgkin Lymphomas (R/R NHL)

NCT03930953Lymphoma, Non-Hodgkin

DrugsValemetostat·Tafasitamab·Golcadomide·Obinutuzumab

Celgene

Phase 1/2

438

Bergamo, Bologna, Milan, Naples, Pavia

2019-05-20

Active, closed

Daratumumab-bortezomib-dexamethasone (Dara-VCd) vs Bortezomib-Thalidomide-Dexamethasone (VTd), Then Maintenance With Ixazomib (IXA) or IXA-Dara

NCT03896737Multiple Myeloma

DrugDaratumumab

European Myeloma Network B.V.

Phase 2

401

Ancona, Bergamo, Bologna, Brescia, Catania, Genova, Milan, Novara

2019-04-16

Active, closed

A Phase 3 Study to Evaluate the Efficacy and Safety of MGL-3196 (Resmetirom) in Patients With NASH and Fibrosis

NCT03900429NASH - Nonalcoholic Steatohepatitis

DrugResmetirom

Madrigal Pharmaceuticals, Inc.

Phase 3

1,759

Messina, Milan, Novara, Palermo, Roma, Bergamo, Florence, Pisa

2019-03-28

Active, closed

A Trial to Evaluate Efficacy and Safety of Ribociclib With Endocrine Therapy as Adjuvant Treatment in Patients With HR+/HER2- Early Breast Cancer

NCT03701334Early Breast Cancer

DrugRibociclib

Novartis Pharmaceuticals

Phase 3

5,101

Ancona, Bergamo, Bologna, Misterbianco, Milan, Rozzano, Palermo, Aviano

2018-12-07

Active, closed

A Study of Neoadjuvant/Adjuvant Durvalumab for the Treatment of Patients With Resectable Non-small Cell Lung Cancer

NCT03800134Non-Small Cell Lung Cancer

DrugsDurvalumab·Pemetrexed·Gemcitabine·Paclitaxel

AstraZeneca

Phase 3

825

Ancona, Bari, Bergamo, Florence, Milan, Monza, Padova, Roma

2018-12-06

Active, closed

Immunotherapy With Ipilimumab and Nivolumab Preceded or Not by a Targeted Therapy With Encorafenib and Binimetinib

NCT03235245Unresectable Stage III Melanoma, Stage IV Melanoma

DrugsBinimetinib·Encorafenib·Ipilimumab·Nivolumab

European Organisation for Research and Treatment of Cancer - EORTC

Phase 2

271

Bergamo, Naples, Padova, Roma, Siena, Turin, Udine

2018-10-30

Active, closed

National Register of Actionable Mutations

NCT05918666Solid Tumours in Advanced Stages

Federation of Italian Cooperative Oncology Groups

Observational

2,098

Ancona, Arezzo, Avellino, Aviano, Bari, Bergamo, Brindisi, Catania

2018-10-27

Active, closed

Safety and Efficacy of Pembrolizumab Compared to Placebo in Resected High-risk Stage II Melanoma (MK-3475-716/KEYNOTE-716)

NCT03553836Melanoma

DrugsKeytruda·Pembrolizumab

Merck Sharp & Dohme LLC

Phase 3

976

Meldola, Bari, Bergamo, Genova, Milan, Naples, Padova, Roma

2018-09-12

Active, closed

Neoadjuvant Treatment of HER2 Positive Early High-risk and Locally Advanced Breast Cancer

NCT03595592Invasive Breast Cancer

DrugsPerjeta·Herceptin·Tecentriq·Pertuzumab

Fondazione Michelangelo

Phase 3

650

Bergamo, Brindisi, Faenza, Genova, Meldola, Milan, Modena, Negrar

2018-09-07

Recruiting

Treatment Protocol for Children and Adolescents With Acute Lymphoblastic Leukemia - AIEOP-BFM ALL 2017

NCT03643276Acute Lymphoblastic Leukemia, Pediatric

DrugsFludarabine Phosphate·Vindesine·Tioguanin·Erwinase

Martin Schrappe

Phase 3

5,000

Ancona, Bari, Bergamo, Bologna, Brescia, Cagliari, Catania, Catanzaro

2018-07-15

Active, closed

A Study to Compare Zolbetuximab (IMAB362) and Chemotherapy With Placebo and Chemotherapy in Adults With Gastric Cancer.

NCT03504397Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer, Locally Advanced Unresectable Gastric Adenocarcinoma or Cancer, Metastatic Gastric Adenocarcinoma or Cancer, Metastatic Gastroesophageal Junction (GEJ) Adenocarcinoma

DrugsZolbetuximab·Folinic acid·Fluorouracil·Oxaliplatin

Astellas Pharma Global Development, Inc.

Phase 3

565

Meldola, Monza, Vicenza, Ancona, Bergamo, Cremona, Milan, Modena

2018-06-21

Active, closed

An Open-Label Phase lB/II Study of Glofitamab and Atezolizumab or Polatuzumab Vedotin in Adult Patients With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma

NCT03533283Non-Hodgkins Lymphoma

DrugsPolatuzumab Vedotin·Glofitamab·Tocilizumab·Obinutuzumab

Hoffmann-La Roche

Phase 1/2

211

Naples, Bologna, Bergamo, Milan

2018-05-08

By invitation

International Registry of Congenital Portosystemic Shunt (IRCPSS)

NCT06041906Congenital Portosystemic Shunt, CPSS (Congenital Portosystemic Shunt)

Prof. Valérie Mc Lin

Observational

500

Bergamo, Naples, Palermo

2018-04-26

Active, closed

A Study of Relatlimab Plus Nivolumab Versus Nivolumab Alone in Participants With Advanced Melanoma

NCT03470922Melanoma

DrugsRelatlimab·Nivolumab

Bristol-Myers Squibb

Phase 2/3

714

Turin, Bergamo, Milan, Naples, Padova, Siena

2018-04-11

Active, closed

A Study of Erdafitinib in Participants With Metastatic or Locally Advanced Urothelial Cancer

NCT03473743Urothelial Carcinoma

DrugsErdafitinib·Cetrelimab·Cisplatin·Carboplatin

Janssen Research & Development, LLC

Phase 1/2

125

Bergamo, Candiolo, Carpi, Catania, Ferrara, Lecco, Livorno, Milan

2018-04-05

Active, closed

A Study of Erdafitinib Compared With Vinflunine or Docetaxel or Pembrolizumab in Participants With Advanced Urothelial Cancer and Selected Fibroblast Growth Factor Receptor (FGFR) Gene Aberrations

NCT03390504Urothelial Cancer

DrugsVinflunine·Erdafitinib·Docetaxel·Pembrolizumab

Janssen Research & Development, LLC

Phase 3

629

Alessandria, Arezzo, Aviano, Bergamo, Brescia, Cremona, Florence, Genova

2018-03-23

Recruiting

Gene Therapy for Severe Crigler Najjar Syndrome

NCT03466463Crigler-Najjar Syndrome

Genethon

Not applicable

Bergamo, Naples

2018-03-19

Active, closed

A Study to Investigate the Clinical Benefit of Isatuximab in Combination With Bortezomib, Lenalidomide and Dexamethasone in Adults With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant

NCT03319667Plasma Cell Myeloma

DrugsVelcade·Isatuximab·Bortezomib·Lenalidomide

Sanofi

Phase 3

475

Ancona, Bergamo, Bologna, Brescia, Torino

2017-12-07

Active, closed

A Study to Evaluate the Efficacy and Safety of Multiple Targeted Therapies as Treatments for Participants With Non-Small Cell Lung Cancer (NSCLC)

NCT03178552Non-Small Cell Lung Cancer

DrugsCobimetinib·Divarasib·Vemurafenib·Entrectinib

Hoffmann-La Roche

Phase 2/3

1,000

Naples, Meldola, Aviano, Rome, Bergamo, Cremona, Milan, Monza

2017-09-22

Active, closed

ATTUNE Revision System in the Revision Total Knee Arthroplasty Population

NCT03153475Revision Total Knee Arthroplasty

DePuy Orthopaedics

Not applicable

400

Bergamo

2017-05-30

Active, closed

Durvalumab ± Tremelimumab in Combination With Platinum Based Chemotherapy in Untreated Extensive-Stage Small Cell Lung Cancer (CASPIAN)

NCT03043872Small Cell Lung Carcinoma Extensive Disease

DrugsTremelimumab·Etoposide·Durvalumab·Cisplatin

AstraZeneca

Phase 3

987

Bergamo, Meldola, Milan, Palermo, Roma, Terni

2017-03-27

Recruiting

Bergamo Lymphoid Cancer Registry

NCT03131531Hodgkin Lymphoma, Non Hodgkin Lymphoma, Myeloma

A.O. Ospedale Papa Giovanni XXIII

Observational

6,000

Bergamo

2017-03-23

Active, closed

A Study of Venetoclax in Combination With Azacitidine Versus Azacitidine in Treatment Naïve Participants With Acute Myeloid Leukemia Who Are Ineligible for Standard Induction Therapy

NCT02993523Acute Myeloid Leukemia (AML)

DrugsAzacitidine·Venetoclax

AbbVie

Phase 3

443

Lecce, Rome, Ancona, Bergamo, Bologna, Genova, Milan, Naples

2017-02-02

Active, closed

A Study of Acalabrutinib vs Investigator's Choice of Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in R/R CLL

NCT02970318Chronic Lymphocytic Leukemia

DrugsIdelalisib·Acalabrutinib·Bendamustine·Rituximab

Acerta Pharma BV

Phase 3

310

Aviano, Bergamo, Brescia, Florence, Genova, Meldola, Milan, Modena

2017-02-02

Recruiting

Compression Only CPR Versus Standard CPR in Out-Of-Hospital Cardiac Arrest - A Randomized Survival Study

NCT03981107Out-Of-Hospital Cardiac Arrest, Cardiac Arrest, Cardiopulmonary Resuscitation

Karolinska Institutet

Not applicable

3,260

Bergamo

2017-01-01

Active, closed

Roll-over Study to Allow Access to Certinib (LDK378) for Patients Who Are on Ceritinib Treatment in a Novartis-sponsored Study

NCT02584933ALK Positive Malignancies

DrugCeritinib

Novartis Pharmaceuticals

Phase 4

233

Bergamo, Bologna, Brescia, Meldola, Monza, Milan, Rozzano, Modena

2015-12-11

Active, closed

AZD9291 Versus Placebo in Patients With Stage IB-IIIA Non-small Cell Lung Carcinoma, Following Complete Tumour Resection With or Without Adjuvant Chemotherapy.

NCT02511106Stage IB-IIIA Non-small Cell Lung Carcinoma

DrugOsimertinib

AstraZeneca

Phase 3

682

Bari, Bergamo, Bologna, Cremona, Florence, Lucca, Meldola, Milan

2015-10-21

Active, closed

A Study of Nonsteroidal Aromatase Inhibitors Plus Abemaciclib (LY2835219) in Postmenopausal Women With Breast Cancer

NCT02246621Breast Cancer

DrugsAnastrozole·Abemaciclib·Letrozole

Eli Lilly and Company

Phase 3

493

Brindisi, Cona, Genoa, Candiolo, Prato, Negrar, Bergamo, Bologna

2014-11-06

Recruiting

Arrhythmias Detection in a Real World Population

NCT02275637Appropriate and Inappropriate Shock Therapy With ICD, Arrhythmias Detection

Fondazione IRCCS Policlinico San Matteo di Pavia

Observational

10,000

Bergamo, Bologna, Catania, Florence, Milan, Naples, Padua, Pavia

2014-09

Active, closed

Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer

NCT02032823Breast Cancer

DrugOlaparib

AstraZeneca

Phase 3

1,837

Bergamo, Bologna, Bolzano, Castellanza Varese, Lecce, Legnago, Milan, Modena

2014-04-22

Active, closed

CONcurrent vs SEqueNTial Adjuvant Treatments in Early Breast Cancer

NCT02918084Breast Cancer

DrugsExemestane·Anastrozole·Letrozole

IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy

Phase 3

1,000

Casale Monferrato, Fabriano, Avellino, Bari, Bergamo, Treviglio, Benevento, Brindisi

2013-06

Recruiting

Lysosomal Acid Lipase (LAL) Deficiency Registry

NCT01633489Lysosomal Acid Lipase Deficiency, Cholesterol Ester Storage Disease, Wolman Disease, Acid Cholesteryl Ester Hydrolase Deficiency, Type 2

Alexion Pharmaceuticals, Inc.

Observational

300

Bari, Naples, Udine, Genoa, Bergamo, Milan, Turin, Florence

2013-05-30

Active, closed

Randomized, Double-blind Study Comparing Tremelimumab to Placebo in Subjects With Unresectable Malignant Mesothelioma

NCT01843374Unresectable Pleural or Peritoneal Malignant Mesothelioma

DrugTremelimumab

MedImmune LLC

Phase 2

571

Alessandria, Aviano, Bergamo, Bologna, Candiolo, Genova, Meldola, Milan

2013-05-17

Active, closed

Long-term Study Evaluating the Effect of Givinostat in Patients With Chronic Myeloproliferative Neoplasms

NCT01761968Chronic Myeloproliferative Neoplasms

DrugHydroxyurea

Italfarmaco

Phase 2

Bari, Bergamo, Florence, Milan, Pescara, Pavia, Reggio Calabria, Vicenza

2013-03

Active, closed

Randomized, Open-label, Two-arms, Phase III Comparative Study Assessing the Role of Involved Mediastinal Radiotherapy After Rituximab Containing Chemotherapy Regimens to Patients With Newly Diagnosed Primary Mediastinal Large B-Cell Lymphoma

NCT01599559Primary Mediastinal B-cell Lymphoma

International Extranodal Lymphoma Study Group (IELSG)

Not applicable

540

Alessandria, Ancona, Aviano, Bari, Barletta, Bergamo, Bologna, Bolzano

2012-10

Recruiting

International Registry of Accidental Hypothermia

NCT06200285Accidental Hypothermia

University Hospital, Geneva

Observational

500

Bergamo, Bolzano, Trento

2008-10-01

Active, closed

Comparison of Fulvestrant (FASLODEX™) 250 mg and 500 mg in Postmenopausal Women With Oestrogen Receptor Positive Advanced Breast Cancer Progressing or Relapsing After Previous Endocrine Therapy.

NCT00099437Breast Cancer

DrugFulvestrant

AstraZeneca

Phase 3

736

Aviano, Bergamo, Carpi, Genova, Prato, Reggio Emilia, Varese

2005-02-13

By invitation

EuroSIDA - Clinical and Virological Outcome of European Patients Infected With HIV

NCT02699736HIV, Hepatitis B, Hepatitis C, AIDS

Copenhagen University Hospital, Rigshospitalet

Observational

23,000

Bergamo, Milan, Modena, Naples, Rome

1994-01

Cite this view

Priya Life Science (2026). Clinical trial register: studies with an Italian investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 9 October 2026. https://priyalifescience.com/clinical-trials-italy/city/bergamo

Query this register directly

GET /api/trials?country=in&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in Italy and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 6,778 studies in total at the last sync on 08 Oct 2026, 03:19 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 370 of those studies with a site in Bergamo.

How many clinical trials are recruiting in Bergamo?

206 of the 370 studies on this page are recruiting new participants as of the 08 Oct 2026, 03:19 UTC sync. A further 10 have not yet opened recruitment, 150 are active but closed to new participants, and 4 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Bergamo), 370 studies
Phase	Studies	Recruiting	Share
Phase 3	163	79	44.1%
Observational	85	64	23%
Phase 2	60	25	16.2%
Not applicable	26	19	7%
Phase 1/2	14	4	3.8%
Phase 1	9	6	2.4%
Phase 2/3	8	5	2.2%
Phase 4	5	4	1.4%

Most active sponsors

Lead sponsors with the most studies (Bergamo)
Lead sponsor	Studies	Recruiting
AstraZeneca	32	15
Hoffmann-La Roche	16	8
Janssen Research & Development, LLC	15	7
Mario Negri Institute for Pharmacological Research	14	8
Bristol-Myers Squibb	13	4
Novartis Pharmaceuticals	13	5
Merck Sharp & Dohme LLC	12	8
FROM- Fondazione per la Ricerca Ospedale di Bergamo- ETS	7	7
Amgen	6	1
Eli Lilly and Company	6	4

Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and China registers.